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INTRODUCTION TO SIDDHA SYSTEM 
 
Siddha system is one of the oldest system of medicine in India. The term ‘Siddha’ 
means achievement and the ‘Siddhars’ were saintly figures. Eighteen ‘Siddhars’ seen to have 
contributed towards the development of this ancient medical system. 
 Siddha system of medicine is based on ‘Saiva Siddhantham’  ‘ Siddha’ is a Tamil 
word that is derived from its root ‘Chit’ which means perfection in life or ‘heavenly bliss’. 
The word ‘Siddha’ denotes one who has achieved some extraordinary powers (Siddhi). This 
achievement was related to the discipline of mind and its superiority over body. It was 
accomplished through both Yoga and Medicine. Thus Siddhars (Practitioners of Siddha) 
became the symbols of Psychosomatic perfection and so the Siddha medicine became a 
combination of medicine and yoga. 
  Mythically the origins of Siddha is attributed to God Siva, who is supposed to have 
handed it down to his consort Parvathi (Shakthi) who in turn passed on the sacred knowledge 
to Nandhi, from where it was transmitted to the Siddhars. 
 
The Siddha medical works were bestowed by the great Siddhars after attaining 
spiritual knowledge through physical perfection and spiritual salvation as explained by the 
Saint in the following verse. 
 Mjp Aikahl;F mUs; kUj;J thq;fj;ij 
 Mjp AikaUshy; mk;GypAs;- NfhWew; 
 nre;jkpohy; $Wjw;Fr; nrk;gts NtoKfd; 
 fe;jkyHr; nrQ;ruNd fhg;G 
The science of Siddha medicine , unlike other systems is a complex system of science 
in as much as it had included in the works of Medicine, Alchemy, Philosopy, Yoga, Varma 
etc, with a view to elevate them in the long run, the level of spiritualism. 
 
Herbal medicines have become popular form of therapy. A drug from an herbal 
source would have ready acceptability by the masses as it suits the psychology of the people 
at large. They are often perceived as being nature and therefore harmless and cheap. The 
herbs also contain lot of essential minerals needed for human health. 
 
 2 
 
The incidence of Kuthi kaal vatham is increasing now-a-days because of negligence, 
It creates a lot of stress and strain to the patient. Hence it needs good medication for 
recovery.  
 
The drug Korai Kizhangu is indicated for Kuthi kaal vatham in Gunapaadam 
Mooligai Vaguppu, So the author has selected this drug to evaluate Analgesic, Anti-
Inflammatory and calcium depletion activity 
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AIM AND OBJECTIVES 
AIM:  
To evaluate the efficacy of Korai Kizhangu Choornam in the management of Kuthi 
kaal vaatham (Calcaneal Spur). 
 
OBJECTIVES: 
The clinical efficacy of Korai Kizhangu Choornam has been evaluated in the 
following aspects. 
 
 Collection of evidences in Siddha aspects 
 Collection of evidences in Chemical aspects 
 Bio-Chemical analysis 
 Physical properties 
 Toxicological study 
 Pharmocological analysis 
 Open clinical trial of Korai Kizhangu Choornam for  Kuthi Kaal Vaatham given 
orally 
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GUNAPADAM ASPECT 
Nfhiuf; fpoq;F 
 
NtWngaH; 
  Kj;jf;fhR 
 
Rit  - JtHg;G 
 
gphpT  - fhHg;G 
 
nra;if: 
 JtHg;gp 
 ntg;gKz;lhf;fp 
 cukhf;fp 
 rpWePHg;ngUf;fp 
 tpaHitg;ngUf;fp 
 cs;sow;wp 
 UJTz;lhf;fp 
 GOtfw;wp 
Fzk;: 
 ,jdhy;> espHr;Ruk;> FUjpaoy; Neha;> Rutiffs;> ePHNtl;if> Kg;gpzp 
fopr;ry;> gapj;jpaNjhlk;> gpj;jjhfk;> fgNuhfk;> Fjpf;fhiyg; gw;wpa thA> the;jp 
Mfpa ,itfs; Nghk;. 
  
rPj Rue;jPHf;FQ; nrk;Gdy;gpj; jk;NghFk; 
 thj Rue;jzpf;Fk; itafj;jpy; - Ntij nra;a 
 te;j gpzpianay;yhk; thl;LKj; jf;fhR 
 nfhe;JyTk; thHFONy! $W 
 
 mjprhuk; gpj;jk; mdw;whfk; Iaq; 
 FjpthjQ; Nrhgq; nfhba – KjpHthe;jp 
 ahiuj; njhlHe;jhYk; mt;ttHf;nf yhq;Fsj;Jf; 
 Nfhiuf; fpoq;iff; nfhL 
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kUj;Jtg; gad;fs; 
 Nfhy Tzitf; Fky dlypyL 
 Nfhy Tzitf; nfhLf aj;ij 
 
nghUs;: 
 Nfhiuf;fpoq;fpd; khitf; fpukg;gb cgNahfpg;gpd; fhrNeha; FzkhFk;. 
 
Nfhiu fpoq;Ff; FbePH: 
 Kj;jf; fhR gw;glfk; KjpHe;j tpyhkpr; rpUNtyp 
 Rj;j Rf;F re;jKQ; Rfkha;f; fha;r;rpf; Fbg;gPNuy; 
 rpj;jg; gpuik Ald;gpwe;j NjNd khNd Nrw;fz;zha; 
 gpj;jj; JlNd te;jRuk; Ngrh Njhbg; Ngha;tpLNk. 
nghUs;: 
 Nfhiuf; fpoq;F> gw;glhfk;> tpyhkpr;R> ntl;bNtH> Rf;F> re;jdk; ,tw;iwr; 
rkkha;f; fye;J fha;r;rpf; Fbf;fpy;> gpj;jRuk; NgrhJ Xbg;NghFk;. 
 
 Kbj;Jf; fdj;j fUq;Foyha; Kj;jf; fhR khk;gl;il 
 ,bj;Jk; nghbj;Jk; gpl;lhf;fp apWfg; gpope;jpl; ljptplak; 
 jbj;j ,ytk; gprpNdhL jfik ngwNt nfhs;thNay; 
 Jbj;J tpOe;j tjprhu Ruj;ijg; Nghf;FQ; nrhd;NdhNk. 
 
nghUs;: 
 Nfhiuf;fpoq;F khk;gl;il Mfpa ,uz;ilAk;> ,bj;Jg; nghbahf;fpg; gpl;L 
nra;J> mij ed;wha;g; gpope;njLj;j rhw;wpy;> mjptplak; ,ytk;gprpd; ,tw;iwr; 
NrHj;J> jf;f mstpy; cl;nfhs;s> fopr;ry;> Ruk; jPUk;. 
 Nfhiuf; fpoq;fpd; FbePiuf; fopr;ry;> Fd;kk;> the;jp KjypaitfSf;Ff; 
nfhLf;fyhk;. 
 ,Q;rp> Nfhiuf;fpoq;F ,t;tpuz;ilAk; ,bj;Jj; Njd; tpl;liuj;J xU rpW 
Rz;il msT nfhLf;f> rPjf;fopr;ry;Nghk;. 
 gr;irfpoq;if miuj;J khHgpy; gw;wplg; ghy; Ruf;Fk;> Njs;fb thapYk; 
gw;wplyhk;.  clypy; g+rptu tpaHit ehw;wk; tpyFk;. 
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 Nfhiuf; fpoq;F> Nga;g;Gly;> jphpgiy> jpuhl;ir> Ntk;G> ntl;ghiy ,itfis 
tiff;F 8 fpuhk; vLj;J Kiwg;gb FbePhpl;Lf; nfhLf;f> Ruk; ePq;Fk;. 
 mgpdp> fQ;rh Kjypa eQ;Rf;F> Nfhiuf;fpoq;F> ,iyf;fs;spNtH> trk;G> 
Rf;F ,itfis tiff;F 8 fpuhk; vLj;J> Kiwg;gb FbePhpl;Lf; nfhLf;fg; Nghk;. 
 Foe;ijfspd; IaRuj;jpw;Ff; Nfhiu NrHe;j kUe;J gad;gLk;.   
 
Nfhiuf;fpoq;F KOFePH: 
 Nfhiuf;fpoq;F> jphpgiy> kUf;fhiu> Gq;F> nfhd;iw> thYOit> 
thw;NfhJik> Vopiyg;ghiy> Nfh\;lk;> Qhoy;> kukQ;rs;> ntz;fLF ,tw;iw 
ePhpypl;Lf; fha;r;rp ePuhb tu> ngUNeha;> nrhwp tPf;fk;> ghz;L ePq;Fk;. 
 
 Nfhiuf;fpoq;F> rPe;jpy;> kukQ;rs;> md;dNgjp> Nfh\;lk;>  nts;sp Nyhj;jpuk;> 
fe;jfk;> rhk;gpuhzp> tha;tplq;fk;> kNdhrpiy> jhsfk;> myprpg;gl;lil ,tw;iwg; 
nghbj;J> Njfj;jpy; vz;nza; jltp> mjd;gpd; Nkw;gb nghbiaj; Nja;f;f> 
rUkg;gil rpuq;F ePq;Fk;. 
 
 Nfhiuf;fpoq;F kpf;f thridAs;sJ.  ,J ,Ujaj;jpw;Fk;> tapw;wpw;Fk; 
tYit nfhLf;Fk;. 
 twl;rpia cz;lhf;Fk;. 
 tpaHitia gpwg;gpf;Fk; 
 ePiug;Nghf;Fk; 
 $e;jy; tsu ,J cgNahfkhfpd;wJ 
 
Nfhiuf;fpoq;F NrUk; thj Neha;f;fhd kUe;Jfs; 
1. njhe;j Ruf; FbePH9 
NrUk; ruf;Ffs; 
 rpWNjf;F   Njtjhuk; 
 gw;glhfk;   Nfh\;lk;>  
Nfhiuf;fpoq;F  Nga;Gly; 
 rPe;jpy;nfhb   Rf;F 
 ed;dhhp 
 rpWfhQ;nrhwp. 
 ,tw;iw FbePhpypl;L nfhLf;f thjk;> gpj;jk;> m];jpRuk; jPUk;. 
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2. jphpNyhf R+lhkzp khj;jpiu:10 
NrUk; ruf;Ffs; 
 Rj;jp nra;j nfshp ghlhzk; 
 Rj;jp nra;j ur fw;g+uk; 
 fQ;rh 
 Nfhiuf;fpoq;F 
 ntbAg;G 
 fw;flf rpq;fp 
 mjpkJuk; 
 mf;fufhuk;; 
 ,r;ruf;Ffis vYkpr;rk;gor; rhw;why; 1 rhkKk;> ,Q;rpr;rhw;why; 4 rhkKk; 
Kiyg;ghyhy; 2 rhkKk; miuj;J rpWgapW msT khj;jpiu nra;J ½ - 1 khj;jpiu 
msT nfhLf;fTk; 
 jPUk; Neha;fs;: 
 rd;dp – 13 
    Njhrk; 
 thjk; - 80 
3. mtpgj;jpr; R+uzk;:11 
NrUk; ruf;Ffs; 
 ney;yp Ks;sp       tha;tplq;fk; 
 fLf;fha;j; Njhy;       kpsF 
 Rf;F     Vyf;fha; 
 ,ytq;fg;gj;hp    ,ytq;fg;gl;il 
 jpg;gpyp    Nfhiuf;fpoq;F 
                       - ,itfs; tiff;F 1 gyk; 
 rptij NtHr;R+uzk;  - 3 gyk; 
 msT    - 1 tuhfd; 
 mDghdk;   -  nte;ePH 
jPUk; Neha;fs; 
 R+iy> mf;fpdp ke;jk;> thjNeha;> gpj;j Nuhfq;fs; 
4. uh[ khHj;jhz;l Nyfpak;:10 
msT - ghf;fsT 
ehs; - 2 Ntis> 48 ehs; 
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jPUk;Neha;fs; - thjk; 80> Fd;kk; 8> gPeprk;> rd;dp> Ruk;> the;jp> 
mf;fpdpke;jk; 
 
5. Glyhjp Ff;fpy; nea;:7 
msT -  1 ¼ -  1 ½ tuhfd;> 1 Ntis NkYf;Fk; cgNahfpf;fTk;> 
erpaKk; nra;aTk;.. 
jPUk;Neha;fs;: 
 vy;yh tif tPf;fq;fs;> thjk;> vy;yh tif Gz;fs;> fz;lkhiy> 
gTj;jpuk;> gpuNkfk;> Nrhif> Fd;kk;> gykhd Neha;f;F ,JNt rQ;rPtp. 
 
 
6. Xrhjpgjp Nyfpak;:10 
msT – 1 tuhfd;> 2 Ntis 
jPUk; Neha;fs;: 
thjk; - 80> gpj;jk;> fphpr;ruk;> R+iy> Fd;kk;> ghz;L> Nrhif> Nkfk;. 
 
Nfhiuf;fpoq;F NrUk; gpw kUe;Jfs; 
1. fl;Lthjp khj;jpiu4 
2. mWfk;NtH ijyk;4 
3. [fd; Nkhfdg; nghb4 
4. fUizf; fpoq;F Nyfpak;4 
5. Ru`u khj;jpiu8 
6. re;jdf; FbePH8 
7. fhkfsh urk;6 
8. rPufhjp ,sfk;7 
9. jhspr ,sfk;7 
10. kd;kj fhkpdp Nyfpak;.7 
11. jdpthj Ruf; FbePH8 
12. gpj;j Ruf;FbePH8 
13. fgRuf; FbePH8 
14. FspHRu FbePH8 
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15. gapj;jpa Ruf;FbePH8 
16. Njhrkhj;jpiu9 
17. tpy;thjpj;ijyk;9 
18. rfy Ruehrj; ijyk;9 
19. jphpNyhr;rd fpUjk;. 10; 
20. kfh mRtfe;jp urhadk;.10 
21. ,q;Fthjp cUz;il11 
22. rhjpypq;f Fspif11 
23. re;jdhjpr; R+uzk;12 
 24. rk;gPuj; ijyk;.12 
 
 
BOTANICAL ASPECT 
CYPERUS ROTUNDUS Linn. 
 
CLASSIFICATION: 
 
Kingdom  - Plantae 
Subkingdom - Tracheobionta 
Superdivision - Spermatophyta 
Division  - Magnoliophyta 
Class  - Monocotyledons 
Subclass  - Commelinidae 
Order  - Cyperales 
Family  - Cyperaceae 
Genus  - Cyperus 
Species  - rotundus 
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VERNACULAR NAMES18 
 
Tamil  - Korai Kizhangu 
English  - Nut grass 
Hindi  - Nagarmotha, Motha 
Kannada  - Tungegadde, Tungahulli 
Malayalam - Muttanna 
Sanskrit  - Musta, Mustaka 
Telugu  - Tunga, Musta 
 
HABITAT:18 
          Throughout India, as a weed upto an elevation of 2000m. 
 
HABIT:21 
 
              This is grass like herb. It has tuberous roots or rhizomes that are fragrant. It is a 
perennial plant, which may reach a height of upto 40cm.  
 
Tuber - Hard, ovoid, tunicate black fragrant 0.8-2.5 cm dm 
 
Root - Fibres clothed with flexuous hairs 
 
Stems - Subsolitary 10-75 cm long, triquetrous at the top, sometimes  
tuberous at the base. 
 
      Leaves - Shorter or Larger than the stem, narrowly linear 4-8mm broad. 
 
Umbel - Simple or compound, ray 2-8. The inflorescence sometimes  
contracted into a head, occasionally of only one spikelet. 
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CHEMICAL CONSTITUENTS:22 
Chemicals include 1,8 – cineole, 4-α, 5- α, oxidoeuderm-11-en-3- α-ol, α-cyperone, α-
rotunol, β-cyperone, β-pinene, β-rotunol, β-selinene, camphene, cyperene, cyperol, 
cyperolone, D-epoxyguaiene, D-fructose, D-glucose, flavanoids. 
 
 γ-Cymene, Iso-cyperol, Linoleic acid, Linolenic acid, Magnesium, Manganese, 
Mustakone, Myristic acid, Oleanolic acid, Oleic acid, P-cymol, Pectin, polyphenols, 
Rotundene, Rotundenol, Rotundone, Sitosterol, Stearic acid, Sugeonol. 
 
 
PHARMOCOLOGICAL ACTIVITES:22,23 
       The essential oil exhibited transquillising activity. 
The alcoholic extract exhibited diruetic effect in rats. 
The extract showed protection against diarrhoea. 
 
It was found in animal studies that water and alcoholic extracts of cyperus rotundus 
exhibited Lipolytic action to mobilise fat from adipose tissues & helps in the reduction of 
obesity. 
 
   Experiments showed that the drug is effective in rats and humans by releasing 
enhanced concentration of biogenic amines from nerve terminals of the brain. This 
suppresses an appetite centre. 
 
 Sitosterol exhibited significant antipyretic effect against pyrexia by Brewer’s 
yeast.The result was compared with acetyl salicylic acid.  
 
 
 
 
 
 
 
 
 12 
 
MATERIALS AND METHODS 
 
 
COLLECTION OF DRUG: 
The drug Korai Kizhangu was collected from the indigenous raw drug stores, 
Tambaram. Its botanical identity was authenticated by Botany Professor of National Institute 
of Siddha. The tubers were dried in sun shade. 
 
PREPARATION OF  DRUG:  
Korai Kizhangu is rinsed thoroughly with water and dried. Then it is grinded into fine 
powder. Then the powder is placed on the cloth tied in the mouth of mud-pot containing 
mixture of milk and water. Then the powder is heated by steam until the milk and water 
mixture is boiled upto 2/3 of initial quantity. 
 
STORAGE OF CHOORNAM: 
The Choornam was stored in a dry air-tight container. Life span of choornam is 3 
months from the date of preparation. It was used within that period. 
 
INTENDED THERAPEUTIC DOSE & DURATION 
1 gm two times a day with honey, after food for 48 days. 
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BIO CHEMICAL ANALYSIS 
CHEMICAL  ANALYSIS  OF    KORAI   KIZHANGU  CHOORNAM 
 
 
SI. NO EXPERIMENT  OBSERVATION  INFERENCE  
1. Appearance of the sample  Dark green colour  
2. Solubility: 
a. A little of the sample is   shaken 
well with distilled    water 
b. A little of the sample is shaken 
well with con Hcl/con H2SO4 
 
Sparingly soluble 
 
 
Completely soluble 
 
 
 
 
Absence of silicate  
3. Action of Heat: 
   A Small amount of the sample is 
taken in a dry test tube and heated 
gently at first and then strongly  
 
White fumes gas not 
evolved 
 
No brown fumes   
 
Absence of carbonate 
 
Absence of Nitrate 
4. Flame Test: 
   A Small amount of the sample is 
made in to a paste with con. Hcl in a 
watch glass and introduced into non-
luminous part of the Bunsen flame  
 
Bluish green colour 
flame is appeared  
 
Presence of Copper 
5. Ash Test: 
  A  filter paper is soaked into a 
mixture of sample and add cobalt 
nitrate solution and introduced into 
the Bunsen flame and ignited  
 
Yellow colour flame 
not appeared  
 
Absence of sodium  
 
 
 
PREPARATION OF EXTRACT: 
 5gm of Korai kizhangu choornam is weighted accurately and placed in a 250ml clean 
beaker and added with 50ml of distilled water. Then it is boiled well for about 10 minutes. 
Then it is cooled and filtered in a 100ml volumetric flask and made up to 100ml with 
distilled water.  
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SL.NO EXPERIMENT  OBSERVATION  INFERENCE  
I  Test For Acid Radicals    
1.  Test For Sulphate: 
a. 2ml of the above prepared 
extract is taken in a test 
tube, to this, add 2ml of 
4% ammonium oxalate 
solution  
 
b.     2ml of the above prepared 
extract is added with 2ml of dil, 
Hcl is added until the 
effervescence ceases off. Then 
2ml of Barium chloride solution 
is added  
 
No cloudy 
appearance present.  
 
 
 
 
No white precipitate 
insoluble in  
con, Hcl  
 
Absence of sulphate. 
 
 
 
 
 
Absence of sulphate.  
2.  Test For Chloride: 
      2ml of the above prepared 
extract is added with dill. HNO3 
till the effervescence ceases. 
Then 2ml of silver nitrate 
solution is added  
 
No cloudy 
appearance  
 
Absence of chloride  
3. Test For Phosphate: 
  2ml of the extract is treated 
with 2ml of ammonium 
molybdate solution and 2ml of 
con. HNO3   
 
No cloudy yellow 
appearance  
 
Absence of Phosphate 
4. Test For Carbonate: 
    2ml of the extract is treated  
with 2ml of magnesium sulphate 
solution.  
 
No cloudy 
appearance  
 
Absence of carbonate  
5. Test For Nitrate:  
   1gm of the substance is heated 
 
No characteristic 
 
Absence of Nitrate 
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with copper turning and 
concentrated H2SO4 and viewed 
the test tube vertically down  
    
changes   
 
 
6 Test For Sulphide: 
   1gm of the substance is treated 
with 2ml of con. Hcl  
 
Colourless, no rotten 
egg smelling gas  
 
Absence of sulphide 
7. Test For Fluoride & Oxalate: 
   2ml of extract is added with 
2ml of dil acetic acid and 2ml of 
calcium chloride solution and 
heated  
 
No cloudy 
appearance  
 
Absence of fluoride and 
oxalate  
8. Test For Nitrite: 
  3 drops of the extract is placed 
on a filter paper, on that 2drops 
of acetic acid and 2 drops of 
benzidine solution is placed.  
 
No reaction  
 
Absence of Nitrite  
9. Test For Borate: 
   2  Pinches of the substance is 
made into paste by using 
sulphric acid and alcohol (95%) 
and introduced into               
flame  
 
No Bluish green 
colour flame 
appeared  
 
Absence of  Borate  
II Test For Basic Radicals    
1. Test For Lead 
   2ml of the extract is added 
with 2ml of potassium iodide 
solution  
 
No yellow precipitate 
 
Absence of lead  
2. Test For Copper 
a. One pinch of substance is 
made in to paste with con. 
Hcl in a watch glass and 
 
Blue flame  
 
 
 
Presence of Copper 
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introduced into the non-
luminous part of the Bunsen 
flame.  
b. 2ml of extract is added with 
excess of ammonia solution 
 
 
 
Blue precipitate 
 
 
 
Presence of Copper 
 
3. 
 
Test For Aluminium: 
    To the 2ml of the extract 
sodium hydroxide is added in 
drops to excess  
 
No characteristic 
changes  
 
Absence of aluminium  
 
4. 
 
Test For Iron: 
a. To the 2ml of extract add 
2ml of ammonium 
thiocyanate  solution  
b. To the 2ml of extract add 
2ml ammonium thiocynate 
solution and 2ml of con 
HNO3 is added  
 
 
Blood red colour is 
not appeared  
 
No red colour 
developed  
 
 
 
Absence of Iron  
 
 
Absence of Iron 
5. Test For Zinc  
   To 2ml of the extract sodium 
hydroxide solution is added in 
drops to excess  
 
No white precipitate  
 
Absence Zinc 
6. Test For Calcium 
    2 ml of the extract is added 
with 2ml of 4% ammonium 
oxalate solution 
No Cloudy 
appearance, 
No white precipitate 
is obtained 
Absence Calcium 
7. Test For Maganese 
    To 2ml extract sodium 
hydroxide solution is added in 
drops to excess 
 
 
No White Precipitate 
is obtained 
 
Absence of maganese 
8. Test for Ammonium: Mild reddish brown Absence of ammonium 
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    To 2ml of extract few ml of 
Nessler’s reagent and excess of 
sodium hydroxide solution are 
added 
 
colour is not 
appeared 
9. Test for Potassium: 
    A pinch of substance is treated 
with 2ml of sodium nitrate 
solution and then treated with 
2ml of cobalt nitrate in 30% 
glacial acetic acid 
 
Yellowish precipitate 
is not obtained 
Absence of Potassium 
10. Test for Sodium 
    2 Pinches of the substance is 
made into paste by using Hcl and 
introduced in to the blue flame, 
of Bunsen burner 
Yellow colour flame 
not appeared 
Absence of Sodium 
11. Test for Mercury 
    2 ml of the extract is treated 
with 2ml of sodium hydroxide 
solution 
No yellow precipitate 
is obtained 
Absence of Arsenic 
12. Test for Arsenic: 
    2ml of extract is treated with 
2ml of silver nitrate solution 
No brownish red 
precipitate is obtained
Absence of Arsenic 
III Miscellaneous:   
1. Test For Starch: 
2 ml of extract is treated with 
weak lodine solution 
Blue colour 
developed 
Presence of starch 
2.  Test for Reducing Sugar: 
 5 ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 minutes 
Green colour 
developed 
Presence of Reducing sugar 
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and added 8 to 10 drops of the 
extract and again boil it for 2 
minutes. The Colour changes are 
noted 
3. Test for The Alkaloids: 
a. 2ml of the extract is 
treated with 2ml of 
potassium iodide 
solution. 
b. 2ml of extract is treated 
with 2ml of picric acid. 
c. 2ml of the extract is 
treated with 2ml of 
phosphotungstic acid 
No red colour 
develops 
 
 
 
No Yellow colour 
develops 
No white precipitate 
obtained 
 
 
 
 
 
Absence of Alkaloid 
 
Absence of alkaloid 
4. Test for Tannic Acid: 
  2ml of extract is treated with 
2ml of ferric chloride solution 
 
No black precipitate 
is obtained 
 
Absence of Tannic acid 
5. Test For Unsaturated 
Compound: 
  To the 2ml of extract 2ml of 
potassium permanganate 
solution is added 
 
 
Potassium 
Permanganate is 
decolourised 
 
 
Presence of unsaturated 
compound 
6. Test For Amino Acid: 
  2 Drops of the extract is placed 
on filter paper and dried well 
 
No Violet colour  
Obtained 
 
 
Absence of amino acid 
7. Test for Albumin: 
  2ml of the extract is added with 
2ml of ESBOCH’S reagent 
 
 
No Yellow colour 
precipitate is formed 
 
Absence of albumin 
 
8. Test For Type of Compound: 
2 ml of the extract is treated with 
2ml of ferric chloride solution 
I. No green 
colour            
developed 
I. Absence of 
oxyquinole 
epinephrine and 
 19 
 
  
 
II. No red  colour  
developed 
 
 
III. No violet  
colour           
developed         
 
IV. No blue 
Colour     
developed  
 
V. No black           
colour   
developed  
 
Pyrocatechol 
 
II. Anti pyrine Aliphatic 
amino acids and 
meconic acid are 
absent 
III. Apo morphine 
salicylate and 
resorcinol are absent 
 
IV. Morphine, Phenol, 
cresol and hydro-
quinone are absent 
 
V. Absence of Tannin 
 
 
 
PHYSICAL PROPERTIES 
 
Loss on Drying  
  5gms of material is heated in a  hot oven at 105˚C to constant weight. The percentage 
of loss of weight was calculated.  
 
Determination of ash Value 
 Weight accurately 2-3gms of sample in tarred platinum or silica dish and incinerate at 
a temperature not exceeding 450˚C until free from carbon, cool and weigh. Calculate the 
percentage of ash with reference to the air dried drug.  
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Acid Insoluble ash 
 Boil the ash for 5 minutes with 25ml of 1:1 dilute HCl. Collected the insoluble matter 
in Gooch- crucible on an ash less filter paper, wash with hot water and ignite, cool in a 
dessicator and  weight. Calculate the percentage of acid insoluble ash with reference to the 
air dried drug.  
 
Water Soluble ash 
 To the Gooch crucible containing the total ash, and 25ml of water and boil for 5 
minutes. Collect the insoluble matter in a sintered glass crucible or on ash less filter paper. 
Wash with hot water and ignite in a crucible for 15 minutes at a temperature not exceeding 
450˚C. Subtract the weight of the insoluble matter from the weight of the ash; the difference 
of weight represents the water soluble ash. Calculate the percentage of water soluble ash 
reference to the air dried drug.  
Alkalinity of water soluble ash  
 5gms converted to ash, boiled with water, filtered, Filtrate was titrated against  0.1N 
of HCl  using phenolphthalein as an indicator.  
Alkalinity of water  soluble ash=X x of acid / 0.1 x  W. 
 X= Titre value  
 W= Weight of the materials taken 
 Alkalinity is given as ml of 0.1 N  of HCL equal to 1gm 
pH 
  
 5gms  of   Korai kizhangu chooranam is weighed accurately and placed in clear 
100ml beaker. A few drops of Aquaregia was added and evaporated by heating for few 
minutes. After cooling the content, 50ml of distilled water is added to it and dissolved well. 
Wait for 30 minutes and then apply into PH matter at standard buffer solution at 4.0, 7.0 and 
9.2. 
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PHARMACOLOGICAL STUDY 
 
ACUTE TOXICITY STUDY 
Honey was used as vehicle. Starting dose was 50mg/kg and the subsequent doses used were 
100, 250, 500, 1000 2000 and 4000mg/kg p.o. Korai Kizhangu Choornam suspended in 
honey was administered to the groups of wistar rats in a single oral dose by gavage using a 
feeding needle. The control group received an equal volume of the honey vehicle. Six 
females and males were used for each dosage level. The principles of laboratory animal care 
were followed and the Department’s ethical committee approved the use of the animals and 
the study design. Observations were made and recorded systematically 1, 2, 4 and 24 h after 
substance administration. The visual observations included skin changes, mobility, 
aggressiveness, sensitivity to sound and pain, as well as respiratory movements. They were 
deprived of food, but not water 16–18 h prior to the administration of the test suspension. 
Finally, the number of survivors was noted after 24 h and these animals were then maintained 
for a further 13 days and observations made daily. The toxicological effect was assessed on 
the basis of mortality, which was expressed as LD50.  
 
ANALGESIC  ACTIVITY OF  KORAI  KIZHANGU  CHOORNAM  IN  
LABORATORY  ANIMALS 
 
EXPERIMENTAL 
Animals:  
 Albino rats (120 to 150 g) or albino mice (20 to 30 g) of either sex were taken for the 
study. The analgesic activity was evaluated by administering the varying doses of drug orally 
30 minutes before the experiment. The doses and time were selected based on preliminary 
screening method. 
 
Analgesic effect:  
 This was investigated by using hot plate method and by acetic acid induced 
abdominal constriction assay procedure in mice. In the hot plate method the rats were placed 
on the hot plate at 55.0±1.0oC and the time taken to lick the hind paw (reaction time) was 
noted. The animals having reaction time within 12 seconds were included in the study. The 
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chemical writhing method involved 10.0 mg/kg, i.p. injection of freshly prepared 0.6% acetic 
acid. The number of abdominal constrictions in the following 10 minutes were noted. 
Significant reduction either in the reaction time or abdominal constriction compared with 
vehicle treated animals was considered as antinociceptive response.  
Statistical Analysis 
 The results were statistically analysed using one-way ANOVA followed by Dunnet’s 
“ t ” test. P values <0.05 were considered significant. 
 
ANTIINFLAMMATORY ACTIVITY OF KORAI KIZHANGU 
CHOORNAM  IN ALBINO RATS 
 
INTRODUCTION 
 Literature survey indicates the presence of multiple chemical constituents in this 
Korai Kizhangu Choornam. However, very few references about the evaluation of 
pharmacological activity of the Korai Kizhangu Choornam are available. The Korai 
Kizhangu Choornam are used for the treatment of inflammatory conditions. It was, therefore, 
decided to screen it for anti-inflammatory activity using animal models. 
 
MATERIALS AND METHODS 
 Freshly prepared Korai Kizhangu Choornam was collected directly from the market 
and was authenticated. The pharmacological screening of the Korai Kizhangu Choornam was 
carried out by using standard protocols. The Korai Kizhangu Choornam was suspended in 
honey for administration to albino rats. Albino rats of 150-200 g were used for present 
investigation. They were kept in polypropylene cages in an air-conditioned area at 25 + 2oC 
in 10-14 h light dark cycle. They were provided with balanced pellet feed and tap water ad 
libitum.  
 
Formalin induced rat paw oedema:  
 Twenty four rats were divided into 4 groups of 6 rats each for various treatments as 
shown in Table 6. Subsequently 30 min after above treatment, 0.1ml of 1% formalin was 
injected subcutaneously into the planter region of right hind paw to induce oedema. The paw 
volume was measured initially and at 1, 2, 3 and 4 h after formalin injection using 
plythesmographic method. Percentage inflammation was calculated for comparison. 
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STATISTICAL ANALYSIS:  
The data were analyzed using one-way analysis of variance. One-way ANOVA were carried 
out for the analysis to determine significant overall effects (P< 0.05).  
 
STUDY OF CALCIUM DEPLETION ACTIVITY OF KORAIKIZHANGU 
CHOORNAM IN RODENTS 
 
INTRODUCTION: 
 
 The time of greatest need for consistent, adequate amounts of calcium in the diet is 
during times of rapid growth as in childhood, pregnancy and lactation, to ensure healthy 
development and maintenance of bones and teeth. Calcium metabolism is dependent on 
many other substances. The presence of vitamin D in the form of calciferol is vital for 
calcium to be absorbed from the intestines. One study looking at calcium supplementation 
and increases in bone density found that when given with vitamins and other minerals, 
efficacy of absorption increased almost three times over just calcium supplementation alone. 
This needs to be a consideration in the treatment of osteoporosis.  
   
 Three regulatory mechanisms control serum calcium, the blood calcium level. This is 
very tightly controlled in a narrow range and primarily it is the kidneys that keep it within 
this narrow window of normal. Low levels of calcium can cause hypertension by decreasing 
the vasodilatory response of blood vessels. This is the type of hypertension effectively treated 
by calcium supplements and checking a serum calcium level on newly diagnosed 
hypertension is an important part of the initial workup. Calcium supplementation may help, 
but is not a recommended treatment for other forms of hypertension.  
 
 Calcium plays a vital role in the muscle contraction-relaxation cycle. The most 
important muscle in the body, the heart, is dependent on calcium for healthy functioning. 
Calcium regulates cell wall permeability and the passage of fluids through cell membranes. 
Calcium activates enzymes involved in fat digestion and protein metabolism. A recent study 
showed a decrease in rates of obesity in persons taking calcium supplements on a regular 
basis.  
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Other Facts:  
 Phosphorous displaces calcium. It increases urinary calcium excretion. As serum 
calcium levels go down as a result of this, calcium is leached from bones and teeth eventually 
weakening them. Calcium is a macromineral, as is magnesium, and the amount needed by the 
body per day is much higher than the microminerals, such as zinc. As such, the 
macrominerals can interfere with the absorption of the microminerals. The bulk of the 
macrominerals are probably best taken at a time separate from any micromineral 
supplementation that has been recommended. The medical profession believes that, except 
for gross excess or deficiency, nutrition is of little importance to overall health, the 
information has been largely ignored.  
 
Calcium 
Calcium in the body must be tightly controlled because it is necessary to cell function for 
such things as blood clotting, muscle contraction, enzyme reactions, cellular communication 
and skin differentiation. It also gives bones and teeth their strength. In fact, the hardest 
substance in the human body, tooth enamel, is 95% calcium.  Calcium is rather deficient in 
the environment. The body has developed special mechanisms to extract calcium from 
dietary sources. Normal adults adapt to decreased calcium intake by increasing the fraction of 
dietary calcium absorbed, but absorption is impaired by aging. Some 30-60% of dietary 
intake is normally absorbed. Several hormones are involved in calcium metabolism. Two 
protein hormones, parathyroid hormone and calcitonin, and a derivative of Vitamin D act to 
make sure the body optimally assimilates dietary calcium.  
 
 A deficiency of calcium results in rickets in children and osteomalacia, both of which 
display a lack of bone mineralization. Calcium deficiency may also contribute to 
osteoporosis. Magnesium appears to be involved in the regulation of calcium levels; 
therefore if magnesium levels are low, calcium levels may also be low and unresponsive to 
treatment unless magnesium levels are corrected. Signs of a deficiency include loss of 
appetite, irritability, disorientation, convulsions, and abnormal behavior.  
          Drugs can alter the ability of the body to digest, absorb, synthesize, transport, store, 
metabolize or eliminate nutrients. This situation potentially can cause Nutrient Depletion. 
Quite often, a patient is then placed on additional medication to combat a new set of 
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symptoms. The cascading effect of such an approach to disease management often leads to a 
reduction in the patient's quality of life. In view of these factors, an attempt was made to 
study the calcium depleting action of korai kizhangu choornam in animal models. 
AIM OF THE STUDY: 
 
a) Femur dry weight measurement during Korai kizhangu choornam treatment.  
b) Changes in biochemical parameters in serum. 
c) Histological analyses of cross sections prepared at the tibiofibular junction.  
d) Estimation of serum parathyroid hormone.  
 
EXPERIMENTAL: 
Animals  
 Wistar Albino rats either sex weighing 150-200gm were selected.  They were kept in 
separate cages in different groups and fed with balanced pellet diet and water ad libitum. 24 
animals were selected and they were divided into 3groups in such a way that each group 
contains 6 animals.  The animals were deprived of food and water for 18hrs prior to the 
commencement of experiment.  The drug treatment pattern was as follows 
Group I (control)    - served as control and received 5ml of saline by oral route.   
Group II (Test I)    - served as test and received KKC (200mg/kg) 
Group III (Test II)  - served as test and received KKC (400mg/Kg) 
 After treatment the animals were kept in the metabolic cage. The urine was collected 
in a measuring cylinder for 5 hours. The bladder was emptied by pulling the base of the tail 
of each rat. The total difference in the collected urine volume of the respective test group was 
compared with normal control group. The results were tabulated (table 7). The calcium 
concentration was measured by standard method. 
Serum analysis: 
 After the experimental period, blood was collected from the retro-orbital of eyes of 
rats under anaesthetic conditions and animals were sacrificed by cervical decapitation.  
Serum was separated by centrifugation at 10,000x g for 10 min and analysed for calcium and 
parathormone. 
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Histopathological analysis: 
The tibiotarsal joint of the animals was isolated and subjected for the 
histopathological study. 
Statistical analysis: 
 Results were expressed as mean ± standard deviation. Statistical analysis of the test 
results was carried out by one-way ANOVA, followed by Dunnet’s multiple comparison test. 
The p value <0.05was considered as significant. 
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SIDDHA ASPECT 
 
Fjpfhy; thjk; 
 
Fzk;: 
 rpyUf;F Fjpfhypy; Cd;w Kbahj typ Vw;gl;L> vOe;jTld; elf;f KbahJ.  
elf;f elf;f typ rpwpJ FiwAk;.  ,J NkLgs;sKs;s jiuapy; fhyzp ,y;yhky; 
elg;gjhy; cz;lhfpwJ. 
 
 Fjpfhypd; cl;Gwk; typapUf;Fk;. fhiyj; jiuapy; Cd;w KbahJ.  
Cd;wpdhy; Fj;jy; typ vLf;Fk;.  ,ijj; jhd; Fjpfhy; thjk; vd;W $WthHfs;. 
 tPwpleuk;Gjd;id Ntjid nra;Ak; Nkdp 
  rPwpltypf;Fk; fhiy jpkpHg;Gld; elapyhf;Fk; 
 kPwpa Njisg;NghNy Cd;wpltypf;Fkhfpy; 
  $wpa Fzq;fs; nka;Na Fzq;FjpthjkhNk….. 
fUj;Jiu: 
 Fjpfhy; thjk; Vw;gl;lhy; euk;Gfspy; Ntjid cz;lhFk;.  fhy; typf;Fk;.  
jpkpHg;Gz;lhFk;. fhiy fPNo Cd;wpdhy;> Njs; nfhl;bdhw;Nghy; NtjidAld; 
jhpg;G.  Fj;jy; cz;lhFk;. 
 Fjpjhd; tPq;fpfLj;J nehe;J Fj;Jk;FilAk; 
  elAkpy;iy rhPukjpNy NehntLj;J jf;feuk;G 
jhd; jpkpHj;J _ _ _ _ _ _ _ _ _ _ _ _ 
fUj;Jiu: 
 Fjpthj Neha; Vw;gl;lhy; Fjpfhy; tPq;fp fLj;J Ntjid jUk;.  Fj;jYk;> 
Filr;rYk; Vw;gl;L elf;f ,ayhJ.  clypy; Ntjid Njhd;Wk;.  euk;Gfspy; jpkpHg;G 
fhZk;. 
 NktpNaKoq;fhypd;fPo; kpFj;jpLthje;Ja;j;J 
 MtpAkopf;Fnkj;j mbaJitf;nfl;lhJ 
 jhtpNaFjpapDs;Ns jf;fjha;jpuz;bUf;Fk; 
 ghtpahq;Fjpthjj;jpd; ghpaJnad;W$Nw 
      - A+fp Kdp itj;jpa fhtpak; 
 Koq;fhypd; fPo;thjk; kpFe;J mb vLj;J itf;ftplhJ capHNghFkhW 
typnaLf;Fk;> Fjpfhypy; thjk; jpuz;bUf;Fk;. ,it Fjpthjj;jpd; Fzq;fshFk;. 
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MODERN ASPECT 
Calcaneal Spur 
Definition: An association and calcification resulting from traction of plantar fascia    
upon the periosteum (covering of bone) of the inferior surface of the calcaneum. 
 
Causes of Heel Spurs: 
1. Being overweight 
2. Improper Footwear 
3. Weak calf muscles tend to add pressure to the foot region 
4. Plantar fascitis 
 
Mechanism of Injury: 
There is stress at the plantar (bottom of the foot) aspect of the calcaneus (heel bone) 
at the attachment of the plantar aponuerosis. This stress is caused by excessive running, 
standing, or walking especially when the individual is unaccustomed to the activity. 
Symptoms: 
(i) Constant pain on the undersurface of the heel, which sometimes radiates from the  anterior 
portion into the rest of the plantar aspect of the foot. 
 
(ii) Pain occurs on standing, walking and it is relieved by rest. 
 
Signs: 
(i) Localized tenderness is found over the medial portion of the spur. 
(ii) Slight swelling may be observed. 
(iii) Passive dorsiflexion of the toes may accentuate the pain. 
 
Radiographic Appearance: 
Radiographs will show a spur. The lateral radiograph is the best view for visualization 
of this condition, the spurs are frequently bilateral and may be asymptomatic, most centres 
image both sides. 
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CLINICAL STUDY 
For this dissertation study 30 patients were selected and 10 patients were admitted in 
National Institute of Siddha, Gunapaadam IN-Patient ward and 20 patients were treated in 
Out-Patient department with the trial drug. 
 
SELECTION CRITERIA: 
Inclusion Criteria 
¾ Age group 20-60 years 
¾ Willing to attend the OPD once in a week for 7 weeks  
¾ Heel Pain 
¾ X-ray heel shows calcaneal growth. 
 
Exclusion Criteria 
¾ Rheumatoid Arthritis  
¾ Gout 
¾ Osteo-arthritis 
¾ Osteo-malacia 
¾ Osteo-porosis 
¾ Osteo-sarcoma 
¾ Malignancy 
 
Withdrawal Criteria 
¾ Drug Intolerance 
¾ Any other acute illness 
 
Line of treatment 
       The drug Korai kizhangu choornam was administered internally in dose of 1 gm two 
times a day with the vehicle honey, after food. 
Diet restriction 
Patient were advised to avoid: 
              Tomato, Cabbage, Cauli flower,  Potato,  Green plantain, Tamarind, Brinjal, Bitter 
guard and Sesban. 
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RESULTS AND OBSERVATION 
Results of Bio-chemical analysis of Korai Kizhangu Choornam : 
Table 1. STANDARDISATION PARAMETERS 
 
Table 2. QUALITATIVE ANALYSIS: 
S.NO PARAMETERS RESULTS 
1 Copper Present 
2 Manganese Present 
3 Starch Present 
4 Unsaturated Compound Present 
5 Reducing Sugar Present 
 
RESULTS OF PHARMACOLOGICAL STUDIES: 
ACUTE TOXICITY-RESULTS OF KORAI KIZHANGU CHOORNAM 
No death was recorded during the treatment period in either the control or treated 
groups given upto the maximum of 4g/kg of Korai Kizhangu Choornam orally. The 
animals did not show any major changes in general behavior or other physiological activities. 
There were no significant behavioural changes and toxic symptoms were observed in treated 
groups of male and female rats. But the symptoms like continuous grooming, aggressive 
behaviour at high dose range, mild sedation, abdominal muscle twitch in few animals was 
generally observed in the animals (Table-3). No pathological alterations were grossly 
detected in vital organs after sacrificing. The organs of treated groups were unremarkable and 
comparable to each sex. This test limit for acute oral toxicity is generally considered to be 4.0 
g/kg body weight. 
  
Sl.No Parameter Results 
1. Loss of drying @ 105º C,  (%) 0.52 
2. Ash  Value  @ 550º C,  (%) 24.29 
3. Water Soluble  (%) 6.77 
4. Alkalinity as CaCo3  in water soluble Ash  (%) 0.28 
5. Acid Insoluble Ash  (%) 0.51 
6. pH at 10% aqueous  solution 5.54 
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Table-3. Incremental dose finding experiment and its Signs of Toxicity 
 
No Treatment 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1 I 50 - - - + + - - - - - - - - - - - - - - - 
2 II 100 - - - + + - - - - - - - - - - - - - - - 
3 III 250 - - - + + - - - - - - - - - - - - - - - 
4 IV 500 - - - + - - - - - - - - - - - - - - - - 
5 V 1000 - - - + - - - - - - + + - - - - - - - - 
6 VI 2000 - - - + - - - - - - + + + - - + - - - - 
7 VII 4000 - + + + + - + + - - + + + - - + - - - - 
 
1.  Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Increased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. 
Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Number of Deaths 
(Mortality) 
 
RESULTS OF ANALGESIC ACTIVITY OF KORAI KIZHANGU CHOORNAM 
 Korai Kizhangu Choornam 400mg/kg increased significantly the paw licking time 
(Table 4). Korai Kizhangu Choornam in mice significantly decreased (Table 5) the number 
of chemical writhings in 10 min compared to control group. 
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Table 4. Effect of Korai Kizhangu Choornam by hot plate method in rats. 
 
Drug and 
Route 
 
Dose 
(mg/kg) 
 
No.of 
animals 
 
Reaction time 
before treatment 
Reaction time (Sec) after KKC treatment   
( mean±SEM) 
15minNS 30min 45min 60min 
Control Saline 6 7.21±1.60 8.51±1.09 8.22±0.70 12.30±1.0 12.15±1.60 
KKC 100 6 8.0±1.55 8.22±0.70 9.18±0.75 12.12±1.0* 11.90±1.11 
Pentazocine 5 6 8.41±1.02 8.16±1.65 10.16±1.18* 14.10±1.50** 12.60±2.72* 
 
Significance relative to control *P<0.05; **P<0.01; ns=not significant. N=6 
6.5
7
7.5
8
8.5
Control / Saline KKC / 100 Pentazocine / 5
BEFORE TREATMENT
 
 
AFTER TREATMENT
8.51 8.22
12.3 12.15
8.22
9.18
12.12 11.9
8.16
10.16
14.1
12.6
0
2
4
6
8
10
12
14
16
15minNS 30min 45min 60min
Control / Saline KKC / 100 Pentazocine / 5
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Table 5. Effect of Korai Kizhangu Choornam on chemical writhings in mice. 
Experiment Number of writhes  Inhibition (%) 
Control 
KKC 100 mg/kg 
Aspirin 150 mg/kg 
52.10±3.88  
33.45±2.52* 
26.10±3.90** 
----- 
65.21 
85.11 
 
Significance relative to control *P<0.05; **P<0.01; ns=not significant N=6 
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RESULTS OF ANTI-INFLAMMATORY ACTIVITY OF  KORAI  KIZHANGU 
CHOORNAM: 
Formalin -Induced rat paw oedema:  
The Korai Kizhangu Choornam as well as Aspirin & Phenyl butazone 20mg/kg 
showed antiphleogestic activity. This antiinflammatory activity was found to be statistically 
significant at the concentration, 400 mg/kg, (Table 6).  
Table 6. Acute antiinflammatory activity of Korai Kizhangu Choornam on formalin 
induced rat paw oedema. 
S.No Treatment Dose (mg/kg) Mean increase in paw 
volume (ml) 
% Inhibition 
1 Control 2ml/kg 0.75±0.05 - 
2 KKC 400 0.43±0.03* 44 
3  Aspirin 150 0.31±0.07** 60 
4 Phynyl butazone 20 0.28±0.06** 63 
Significance relative to control *P<0.05; **P<0.01; N=6 Values are mean + SEM; n=6 in 
each group. 
ACUTE ANTIINFLAMMATORY ACTIVITY
44
60
63
KKC  Aspirin Phynyl butazone
 
RESULTS OF CALCIUM  DEPLETION ACTIVITY OF KORAI  KIZHANGU 
CHOORNAM: 
                      Results shows that Korai Kizhangu Choornam possess insignificant depleting 
action of calcium (P <0.01). There is significant kaliuretic and chloriuretic effect was 
observed in the Korai Kizhangu Choornam treated animals and their urine sample (Table 
no.7 and 8). Urine production is more in 400mg / kg of Korai Kizhangu Choornam at 24th hr 
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was moderately significant compared to control. The calcium, phosphate level in rats, 
calcium, phosphate level in blood serum and heamatological parameters has been shows to 
be moderately lowered. 
Table-7. EFFECT OF KORAI KIZHANGU CHOORNAM ON SERUM AND 
URINARY PARAMETERS IN EXPERIMENTAL ANIMALS 
S. No. Parameter (U) Group – I 
Normal 
Group – II 
KKC (200mg/kg) 
Group – III 
KKC (400mg/kg) 
1. Urine(mg/dl)  
Calcium 
Magnesium 
 
3.01±0.119 
58.16±0.21 
 
4.55±0.067* 
54.19±1.87 
 
5.15±0.042** 
61.06±2.20 
2. Serum (mg/dl)  
Calcium 
Magnesium 
 
5.63±0.049* 
55.00±0.09 
 
7.71±0.060* 
56.14±1.46 
 
3.47±0.079** 
74.10±0.60 
3. Parathormone 108.57±11.22 56.23±6.51 96.62±8.10* 
4. ALP 221.17±80.57 265.67±45.98 199.83±19.60 
5. TC 10427±601.34 14976±747.62** 12154±316.21** 
6. Femoral bone weight 
(in gms) 
1.6gms 1.4gms 1.6gms 
7. SGOT 178.83±27.69 172±18.58 171±16.79 
8. SGPT 59.67±7.87 56.33±7.39 56.83±7.39 
9. PT 27.42±1.64 24.63±0.96 30.38±2.52 
10. CT 1.5min 1.8min 2.1min 
11. BT 2.1 min 2.0 min 2.0 min 
12. Calcitonin >100 >48 >65 
Significance relative to control *P<0.05; **P<0.01; ns=not significant. N=6 
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Table-8. EFFECT OF KORAI  KIZHANGU CHOORNAM 
ON URINARY PARAMETERS 
 
 
S. No. 
 
No.of 
Animals 
 
Treatment 
 
Dose 
 
Concentration of ions (Electrolytes) 
Na+ mEq/Lit K+ 
mEq/Lit 
Cl- mEq/Lit
1 6     Control 
5ml/kg 
saline 
129.64±10.50 44.52±2.17 109.31±11.80
2 6     Test –I 
200mg/kg  
oral route 
136.3±11.21 31.6±2.32*
* 
110.37±9.12 
3 6 Test –II  
400mg/kg 
oral route 
126.25±11.21 27.8±1.28* 110.83±8.82 
Significance relative to control *P<0.05; **P<0.01; ns=not significant. N=6 
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CLINICAL ASSESSMENT: 
Table 9. Gender Distribution: 
Gender 
Cases 
No. Percentage 
Male 6 20 
Female 24 80 
Total 30 100 
 
GENDER DISTRIBUTION
20
80
Male Female
 
 
According to Gender distribution :-  
20% of cases were in male.  
80% of cases were in female. 
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Table 10. Age Distribution: 
Age 
Cases 
No. Percentage 
21-30 2 6.7 
31-40 7 23.3 
41-50 12 40 
51-60 9 30 
6.7
23.3
40
30
0
10
20
30
40
21-30 31-40 41-50 51-60
YEARS
AGE DISTRIBUTION
 
According to Age distribution :- 
6.7% of cases were in below 30.  23.3% of cases were in below 40. 
40% of cases were in below 50.  30% of cases were in below 60. 
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Table 11. Distribution of Clinical Symptoms of Kuthi Kaal Vaatham before and after treatment. 
 
S. No Signs & Symptoms Before 
Treatment 
After 
Treatment 
Improvement 
1 Tenderness 30 5 83% 
2 Morning Stiffness 25 5 80% 
3 Localised Swelling of the 
Foot 
15 0 100% 
4 Warmth 12 0 100% 
5 Colour Change - - - 
6 Pain during rest 16 2 87.5 % 
7 Pain during standing 22 3 86.36% 
8 Pain during walking 26 3 88.5 % 
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CLINICAL SYMPTOMS OF KUTHI KAAL VAATHAM BEFORE AND AFTER 
TREATMENT.
Before Treatment After Treatment
 
OBSERVATION: 
 
Tenderness: 
Out of 30 cases with initial symptom of Tenderness only 5 cases had Tenderness AT. ie., 83% of cases did not have 
tenderness. 
 
Morning Stiffness: 
Out of 25 cases with initial symptom of Morning Stiffness only 5 cases had Morning Stiffness AT. ie., 80% of cases did not 
have Morning Stiffness. 
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Localised Swelling of the Foot: 
Out of 15 cases with initial symptom of Localised Swelling of the Foot, no cases had Localised Swelling of the Foot AT. ie., 
100% of cases did not have Localised Swelling of the Foot. 
Warmth: 
Out of 12 cases with initial symptom of Warmth, no cases had Warmth AT. ie., 100% of cases did not have Warmth. 
 
Colour Change 
No cases found to have colour change BT & AT. 
 
Pain during rest: 
Out of 16 cases with initial symptom of Pain during rest, only 2 cases had Pain during rest AT. ie., 87.5 % of cases did not 
have Pain during rest. 
Pain during standing: 
Out of 22 cases with initial symptom of Pain during standing, only 3 cases had Pain during standing AT. ie., 86.36 % of cases 
did not have Pain during standing. 
 
Pain during walking: 
Out of 26 cases with initial symptom of Pain during walking, only 3 cases had Pain during walking AT. ie., 88.5 % of cases 
did not have Pain during walking.                                  
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CASE SHEET OF  KUTHII KAAL  VATHAM PATIENTS 
S 
NO. 
O.P/ 
I.PNo NAME 
AGE/
SEX TENDERNES
MORNING 
STIFFNESS 
LOCALISED 
SWELLING 
OF THE 
FFOD 
WARMTH COLOUR CHANGE 
PAIN 
DURING 
REST 
PAIN 
DURING 
STANDING
PAIN 
DURING 
WALKING
    BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT
1 AG781 Tamilselvi 27/F + - + + - - - - - - - - + - + - 
2 AF8901 Kaveri 42/F + + + - + - + - - - + - - - + - 
3 AG2076 Esther 53/F + + + + + - + - - - + + + - + - 
4 AG2142 Vasantha 52/F + - + + - - - - - - - + + - + + 
5 AG2157 Kowsalya 40/F + - + - + - + - - - + - + - + + 
6 AG2470 Rose 40/F + - + - + - + - - - + - + - + + 
7 AG2945 Anjali 46/F + + + - + - - - - - + - + - + - 
8 AG3630 Rajalakshmi 50/F + - + - + - + - - - + - + - + - 
9 AG3923 Muhammadimran 35/M + - + - + - + - - - + - + - + - 
10 AG4081 Balakrishnan 42/M + - + + + - + - - - - - + - + - 
11 AG4403 Pannerselvan 40/M + - + - - - - - - - + - + - + - 
12 AG4413 Palaniyammal 40/F + - + - - - - - - - - - - - + - 
13 AG5701 Santhi 42/F + - + - - - - - - - - - - - + - 
14 AG5121 Sudha 32/F + - + - - - -- - -  - - - - - - 
15 AG6238 Arumaikan 43/F + - + - - - - - - - + - - - + - 
16 AG6237 Manjula 29/F + - + - - - - - - - - - + - + - 
17 AG6236 Baskaran 49/M + - + - - - - - - - - - + - - - 
18 AG2945 Jothi 41/F + - + - - - - - - - - - + - + - 
19 AG2114 Danalakshmi 46/F + - + - - - - - - - - - - - - - 
20 AG5126 Amaravathi 36/F + - + - + - + - - - + - + - + - 
21 782/IP Govindammal 50/F + + + - + - - - - - + - + - + - 
22 750/IP Devi 45/F + + - - - - - - - - + - - + + - 
23 787/IP Vijayalakshmi 54/F + - + + + - + - - - - - + + + - 
24 782/IP Santhi 52/F + - - + + - + - - - + - + - + - 
25 852/IP Gangadevi 52/F + - - - + - + - - - - - + - + - 
26 849/IP Lakshmi 45/F + - + - + - + - - - + - + + + - 
27 838/IP Niraimathi 54/F + - + - + - - - - - - - + - + - 
28 858/IP Amaravathi 60/F + - - - - - - - - - - - + - + - 
29 1262/IP Govindasami 40/M + - - - - - - - - - + - - - - - 
30 1181/IP Janarthanan 55/M + - + - - - - - - - + - + - + - 
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HAEMATOLOGICAL REPORT  OF  KUTHI KAALVATHAM  PATIENTS 
 
SNO 
 
OP/IP 
NO 
 
NAME 
 
A/S 
BEFORE TREATMENT AFTER TREATMENT 
TC 
Cells/ 
cumm 
DC ESR 
½ /1 
hr 
Hb 
gm% 
TC 
Cells/ 
cumm
DC ESR 
½ /1 
hr 
Hb 
gm% P% L% E% M% P% L% E% M%
1 AG781 Tamilselvi 27/F 6800 50 46 4 0 8/16 11.2 6900 48 48 2 0 4/8 12 
2 AF8901 Kaveri 42/F 6900 52 44 3 1 6/15 11 7000 50 42 3 1 6/12 11.5 
3 AG2076 Esther 53/F 7000 55 42 2 1 6/12 11.5 7000 50 40 2 0 6/12 11.5 
4 AG2142 Vasantha 52/F 7200 50 45 5 0 5/12 11.6 7400 55 40 5 0 5/10 12 
5 AG2157 Kowsalya 40/F 7200 54 43 6 0 3/6 12.1 7200 50 43 5 0 2/4 12 
6 AG2470 Rose 40/F 5200 51 38 6 1 4/8 13.6 6000 50 34 6 0 2/4 13.2 
7 AG2945 Anjali 46/F 6000 52 40 8 1 15/32 13.6 6500 51 40 8 1 10/20 13.6 
8 AG3630 Rajalakshmi 50/F 6500 54 41 6 1 10/22 13.5 6800 51 40 6 1 10/20 15.5 
9 AG3923 Muhammadimran 35/M 7000 50 41 3 0 4/8 15 7200 51 40 3 0 4/8 15.5 
10 AG4081 Balakrishnan 42/M 6800 52 48 2 0 5/10 12.9 6800 50 40 2 0 5/10 13 
11 AG4403 Pannerselvan 40/M 7200 56 40 4 0 6/12 13.6 7400 50 40 2 0 5/10 14 
12 AG4413 Palaniyammal 40/F 7900 50 34 4 0 10/22 13.6 7900 56 30 4 0 5/10 14 
13 AG5701 Santhi 42/F 8000 52 40 2 1 10/20 12.6 8500 50 40 2 0 5/10 13 
14 AG5121 Sudha 32/F 7500 50 40 4 0 10/20 13. 7500 50 40 4 0 5/10 13.5 
15 AG6238 Arumaikan 43/F 6500 60 44 2 0 10/22 12 6500 48 40 4 0 10/20 12 
16 AG6237 Manjula 29/F 6000 54 40 4 1 5/10 10.3 6500 60 40 2 1 5/10 10 
17 AG6236 Baskaran 49/M 7900 53 44 2 0 5/10 12.1 7800 52 40 2 0 5/10 12 
18 AG2945 Jothi 41/F 7100 52 42 4 0 8/16 12.5 7100 52 40 4 0 5/10 12 
19 AG2114 Danalakshmi 46/F 6500 50 46 2 1 5/10 12.1 6500 50 40 2 1 5/10 12.1 
20 AG5126 Amaravathi 36/F 7200 52 40 4 1 5/10 13 7000 50 40 4 0 5/10 13 
21 782/IP Govindammal 50/F 7000 52 40 4 1 4/8 11 7000 52 40 3 0 4/8 11.5 
22 750/IP Devi 45/F 7200 51 40 3 0 2/4 13.1 7000 50 40 2 0 2/4 13 
23 787/IP Vijayalakshmi 54/F 6500 50 40 2 0 6/12 13.1 6500 50 35 2 0 6/12 13 
24 782/IP Santhi 52/F 7400 60 40 4 0 6/12 12 7500 50 40 4 0 6/12 12 
25 852/IP Gangadevi 52/F 7600 56 29 11 0 68/136 11 7200 60 20 10 0 30/60 11 
26 849/IP Lakshmi 45/F 7800 52 39 5 0 6/12 12.6 7800 50 40 4 0 6/12 12 
27 838/IP Niraimathi 54/F 7000 54 45 3 1 8/16 11 7000 50 40 3 0 8/16 10 
28 858/IP Amaravathi 60/F 8100 59 40 4 0 12/24 9.5 8000 54 40 3 0 10/20 9.5 
29 1262/IP Govindasami 40/M 6900 50 33 8 0 48/96 11.8 7000 50 30 6 0 12/24 11 
30 1181/IP Janarthanan 55/M 7000 52 35 3 0 2/4 11.8 8100 52 42 6 0 8/16 11 
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HAEMATOLOGICAL REPORT  FOR  KUTHI KAALVATHAM  PATIENTS 
 
SNO 
 
 
OP/IPNO 
 
NAME 
 
A/S 
BEFORE TREATMENT AFTER TREATMENT 
TRBC/ 
millions 
 
RBS 
mgm/dl 
Urea 
mg% 
Uric 
acid 
mg% 
Creatinine 
mg% 
Choles 
terol 
mg% 
TRBC/ 
millions 
 
RBS 
mgm/dl 
Urea 
mg% 
Uric 
acid 
mg% 
Creatinine 
mg% 
Choles 
terol 
mg% 
1 AG781 Tamilselvi 27/F 3.7 88 20 2.5 0.8 138 3.8 88 21 2.5 0.7 134 
2 AF8901 Kaveri 42/F 3.8 108 29 3 0.8 164 3.8 105 25 3 0.8 162 
3 AG2076 Esther 53/F 3.2 105 25 2.5 0.9 162 3.4 108 25 3.5 0.9 160 
4 AG2142 Vasantha 52/F 3.5 146 27 2.5 0.8 142 4 140 27 3.4 0.8 135 
5 AG2157 Kowsalya 40/F 4 150 22 3 0.8 226 4 150 22 3.1 0.8 220 
6 AG2470 Rose 40/F 4.1 115 25 2.7 0.8 200 4 120 25 2.7 0.8 190 
7 AG2945 Anjali 46/F 2.8 96 38 2.2 0.8 185 4.5 96 38 3.2 0.8 180 
8 AG3630 Rajalakshmi 50/F 3.7 115 25 2.6 0.7 190 3.7 115 24 3.6 0.7 186 
9 AG3923 Muhammadimran 35/M 2.6 100 15 3.5 0.8 245 2.8 115 15 3.2 0.8 220 
10 AG4081 Balakrishnan 42/M 4.2 150 16 2.7 0.9 200 4.2 120 16 2.7 0.9 190 
11 AG4403 Pannerselvan 40/M 4.8 120 18 3.6 0.9 185 4.8 125 18 3.6 0.8 180 
12 AG4413 Palaniyammal 40/F 2.9 80 23 2.6 0.8 207 3.7 85 23 3.5 0.7 190 
13 AG5701 Santhi 42/F 2.7 95 25 3.7 0.8 164 3 90 25 3.6 0.8 160 
14 AG5121 Sudha 32/F 2.5 105 25 2.6 0.7 160 3.5 120 25 3.7 0.8 165 
15 AG6238 Arumaikan 43/F 3.1 86 19 2.7 0.6 154 3.2 87 19 2.7 0.7 150 
16 AG6237 Manjula 29/F 2.9 80 17 3.5 0.8 168 3 80 17 2.7 0.8 160 
17 AG6236 Baskaran 49/M 2.7 82 25 4.5 0.9 170 3.5 80 25 4.7 0.9 172 
18 AG2945 Jothi 41/F 3.2 102 25 4.5 0.9 184 3.5 105 25 4.5 0.8 184 
19 AG2114 Danalakshmi 46/F 4.2 80 24 4.8 0.7 208 4.5 80 24 4.7 0.7 200 
20 AG5126 Amaravathi 36/F 4.1 85 33 2.6 0.6 154 4 80 34 2.6 0.6 154 
21 782/IP Govindammal 50/F 3.5 125 35 2.5 0.7 154 3.8 128 35 2.4 0.7 152 
22 750/IP Devi 45/F 4.2 120 30 2.7 0.6 150 4.2 125 35 2.8 0.6 159 
23 787/IP Vijayalakshmi 54/F 4.1 810 14 2.8 0.6 227 4.2 80 15 2.8 0.6 220 
24 782/IP Santhi 52/F 4 80 21 3.2 1.4 154 4.2 85 20 3.1 1.2 150 
25 852/IP Gangadevi 52/F 3.5 190 22 3.5 1.1 221 3.5 120 23 3.5 1.2 215 
26 849/IP Lakshmi 45/F 3.3 150 28 4 1.5 151 3.4 115 29 4.1 1.4 150 
27 838/IP Niraimathi 54/F 4 128 29 4.2 1.6 200 4.2 120 29 4.1 1.6 190 
28 858/IP Amaravathi 60/F 3.3 108 27 4.3 1.2 196 3.3 108 27 4.2 1.2 190 
29 1262/IP Govindasami 40/M 4 128 26 4.8 1.1 245 4 120 26 4.8 1.2 220 
30 1181/IP Janarthanan 55/M 4.1 107 25 3.6 1.2 226 4 100 25 3.6 1 200s 
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URINE ANALYSIS OF  KUTHI KAAL VATHAM PATIENTS 
 
 
S. 
No 
  
 
 OP/ 
 IPNO 
 
 
NAME 
 
 
A/S 
BEFORE TREATMENT AFTER TREATMENT 
Alb Sug Deposits Alb Sug Deposits 
Pus 
cells 
Epi 
cells 
RBC’s Casts 
/crystals 
Pus 
cells 
Epi 
cells 
RBC’s Casts 
/crystals 
1 AG781 Tamilselvi 27/F Nil Nil 2-3 2-3 Nil Nil Nil Nil 4-6 2-4 Nil Nil 
2 AF8901 Kaveri 42/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-3 2-4 Nil Nil 
3 AG2076 Esther 53/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 5-6 5-6 Nil Nil 
4 AG2142 Vasantha 52/F Nil Nil 4-6 4-6 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
5 AG2157 Kowsalya 40/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
6 AG2470 Rose 40/F Nil Nil 2-4 2-5 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
7 AG2945 Anjali 46/F Nil Nil 2-3 2-4 Nil Nil Nil Nil 2-4 3-4 Nil Nil 
8 AG3630 Rajalakshmi 50/F Nil Nil 4-6 4-6 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
9 AG3923 Muhammadimran 35/M Nil Nil 2-3 2-3 Nil Nil Nil Nil 1-2 2-5 Nil Nil 
10 AG4081 Balakrishnan 42/M Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-3 4-5 Nil Nil 
11 AG4403 Pannerselvan 40/M Nil Nil 4-6 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
12 AG4413 Palaniyammal 40/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
13 AG5701 Santhi 42/F Nil Nil 2-4 4- Nil Nil Nil Nil 1-2 2-4 Nil Nil 
14 AG5121 Sudha 32/F Nil Nil 3-4 4-6 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
15 AG6238 Arumaikan 43/F Nil Nil 1-2 2-6 Nil Nil Nil Nil 1-4 2-4 Nil Nil 
16 AG6237 Manjula 29/F Nil Nil 2-4 4-6 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
17 AG6236 Baskaran 49/M Nil Nil 2-4 2-5 Nil Nil Nil Nil 2-3 2-4 Nil Nil 
18 AG2945 Jothi 41/F Nil Nil 2-3 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
19 AG2114 Danalakshmi 46/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
20 AG5126 Amaravathi 36/F Nil Nil 2-4 4-6 Nil Nil Nil Nil 5-6 2-4 Nil Nil 
21 782/IP Govindammal 50/F Nil Nil 4-6 1-2 Nil Nil Nil Nil 2-3 2-4 Nil Nil 
22 750/IP Devi 45/F Nil Nil 2-4 2-3 Nil Nil Nil Nil 2-4 1-2 Nil Nil 
23 787/IP Vijayalakshmi 54/F Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 1-2 Nil Nil 
24 782/IP Santhi 52/F Nil Nil 3-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
25 852/IP Gangadevi 52/F Nil Nil 2-6 2-4 Nil Nil Nil Nil 1-2 2-5 Nil Nil 
26 849/IP Lakshmi 45/F Nil Nil 2-4 4-6 Nil Nil Nil Nil 1-2 2-3 Nil Nil 
27 838/IP Niraimathi 54/F Nil Nil 2-3 2-5 Nil Nil Nil Nil 1-2 1-3 Nil Nil 
28 858/IP Amaravathi 60/F Nil Nil 2-3 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
29 1262/IP Govindasami 40/M Nil Nil 3-4 1-2 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
30 1181/IP Janarthanan 55/M Nil Nil 2-3 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
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DISCUSSION 
 
 The drug Korai Kizhangu Choornam was selected to find its efficacy in the treatment 
of Kuthi Kaal Vaatham.  
 Literary evidences strongly support the Anti-Inflammatory and analgesic activity of 
the drug.  
 Bio-Chemical analysis of the drug Korai Kizhangu Choornam reveals the presence 
of Copper, Manganese, Starch, Unsaturated compound and reducing sugar.   
 Copper is necessary for the formation of the RBC and other components of the blood 
system and for the healthy growth, development and maintenance of bone, connective tissue, 
brain, heart and many other body organs. Copper like Zinc and Manganese is used to form 
Anti-Inflammatory compounds in the body known as SuperOxide Dimutase.  
 Manganese is essential for normal bone structure reproduction and normal 
functioning of CNS. Bone deformaties occur in all animals in its deficiency. 
Starch is by for most consumed polysaccharides in the human diet. Traditional foods 
such as Cereals, roots and tubers are main source of dietary starch. 
 
Pharmacological Studies:  
Pharmacological studies done in Vel’s college of pharmacy in pallavaram.  
In acute toxicity study oral administration of Korai Kizhangu choornam did not produce any 
mortality in mice upto a dose level of 4gm/kg. This may be due to the broad non-toxic range 
of the drug.  
Korai Kizhangu choornam exhibited significant dose dependent antinociceptive effect 
as measured by hot plate method and chemically induced abdominal constrictions in mice. 
These observations substantiate the findings of clinically in man. 
  The Korai Kizhangu choornam showed antiinflammatory activity, which was found 
to be statistically significant at 400mg/kg concentration in acute formalin induced rat paw 
oedema model. However, this activity was less potent as compared to Phynylbutazone and 
Aspirin. This activity appears to be significant in early phases of inflammation in which 
various biochemicals, viz. histamine, 5-HT, various kinins are involved. The results were 
significant when analysed statistically. Thus, Korai Kizhangu Choornam shows anti-
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inflammatory activity at various acute phases of inflammation and on formation of granular 
tissue.  
Results shows that Korai Kizhangu Choornam possess insignificant depleting action 
of calcium (P <0.01). There is significant kaliuretic and chloriuretic effect was observed in 
the Korai Kizhangu Chooranam treated animals and their urine sample (Table no.7 and 8). 
Urine production is more in 400mg / kg of Korai Kizhangu Chooranam at 24th hr was 
moderately significant compared to control. The calcium, phosphate level in rats, calcium, 
phosphate level in blood serum and heamatological parameters has been shows to be 
moderately lowered. 
 
SIDDHA ASPECT 
The drug Korai Kizhangu Choornam was mentioned in Gunapadam Mooligai 
vaguppu for Kuthi Vatham. 
 mjprhuk; gpj;jk; mdw;whfk; Iaq; 
 FjpthjQ; Nrhgq; nfhba – KjpHthe;jp 
 ahiuj; njhlHe;jhYk; mt;ttHf;nf yhq;Fsj;Jf; 
 Nfhiuf; fpoq;iff; nfhL 
 So the author has selected this drug for evaluation of Analgesic, anti – inflammatory 
and calcium depletion activity. 
SUMMARY AND CONCLUSION 
The drug Korai Kizhangu Choornam has selected for the study to evaluate its efficacy 
in the management of Kuthi Kaal Vaatham 
The literature collection describes the anti-inflammatory, analgesic and calcium 
depletion activity of the drug Korai Kizhangu Choornam. 
The chemical analysis of the drug Korai Kizhangu Choornam reveals the presence of 
copper, manganese, starch, unsaturated compound and reducing sugar. 
Pharmacological studies showed that the drug has significant anti-inflammatory and 
analgesic activity at the dose of 400 mg/kg and no significant adverse effects. 
The pharmacological screening results showed that the drug  Korai Kizhangu 
Choornam does not possess significant calcium depleting effect.  
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Further it is evident that the drug is not altering the calcium level significantly in 
animal models. It can be suggested that this drug is useful in the treatment of calcaneal spur 
by acting other mechanism but not by depleting the calcium level. 
30 patients with signs & symptoms of Kuthi Kaal Vaatham were selected and a 
thorough observation was made.  
The majority of the patients were female. 
Clinically no adverse effects were reported during the course of treatment. 
The improvement shown after treatment in terms of clinical symptoms viz. 
tenderness, morning stiffness, localised swelling of the foot, warmth, colour change, pain 
during rest, standing and walking were statistically significant. 
Conclusion 
From the pharmacological studies and clinical study, it was concluded that the drug 
Korai Kizhangu choornam  has significant anti-inflammatory and analgesic activity . 
Thus it gives us a new hope in the management of Kuthi Kaal Vatham (Calcaneal spur). 
A STUDY ON PALAGARAI  PARPAM 
 
INTRODUCTION 
 
Among the traditional system of medicine, Siddha system of medicine is not only ancient 
but it has its own enduring properties. In Siddha system, drugs are classified into 3 main 
groups namely Mooligai, Thathu and Jeevam. The class Jeevam consists of animal products 
which bear the medicinal values in abundance. 
 
The Siddha system has got great remedies from animal source. The Palagarai comes 
under the Jeeva vaguppu. In this study the author has undertaken Ven Palagarai for 
experimentation of its medicinal properties. 
 
As per specification given in the Siddha literature “Gunapadam Thathu Jeeva 
Vaguppu”, the Ven Palagarai is better than all other speicies. So the author has selected Ven 
Palagarai for this study. 
 
It is an important animal source belonging to “MOLLUSCA” Phylum, Zoologically 
named Cypraea moneta, linn. 
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The drug has maximum pharmacological and therapeutic effects without any side 
effects. 
 
Leucorrhoea, a vaginal discharge is a universal problem of all women. Female 
genitals are very much prone to infections. Since they are moist more sweaty and covered. 
The drug Palagarai Parpam is indicated for Vellai Noi in Pathartha Guna Vilakkam 
(Thathu Jeeva Varkam) so the author has selected this drug to evaluate Anti-microbial 
activity.  
 
AIM AND OBJECTIVES 
  
AIM:  
 
To evaluate the efficacy of Palagarai parpam in the management of  
Vellai noi [Leucorrhoea] 
 
OBJECTIVES: 
The clinical efficacy of Palagarai parpam has been evaluated in the following aspects. 
 
 Collection of evidences in Siddha aspects 
 Collection of evidences in Chemical aspects 
 Collection of evidences in Zoological aspects 
 Bio-Chemical analysis 
 Physical properties 
 Toxicological study 
 Pharmocological analysis 
 Open clinical trial of Palagarai parpam for Vellai Noi given orally 
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GUNAPADAM ASPECT 
gyfiw 
 
NtWngaHfs;: 
 “kz;zpa ftb Nrhfp tuhbNa gyfiwg;NgH 
                                -  epfz;L 
   fly;gL jputpak; Ie;jpDs; xd;whfpa ,J ftb> Nrhfp> tuhb 
vd;w NtWg;ngaHfshy; toq;fg;gLfpd;wJ. 
 
 Nrhfp guy; tl;b gyfiw nts;thp 
 ahk; ftb Nahly nfd;whd; 
- ehk jPg epfz;L 
vd;gjpypUe;J Nrhfp> guy;> tl;b> gyfiw> nts;thp> ftb vd;w NtWg; 
ngaHfshy; toq;g;gLfpd;wJ 
 
msT: 
 ,jd; cUtk; Gspapd; tpj;J Kjy;> thJikf; nfhl;ilg; gUkdsT ,Uf;Fk;.  
 
epwk;:    
nts;is> kQ;rs;> rptg;G Mfpa %d;W epwq;fspy; ,J fpilf;Fk;.  ntz;zpwg; 
gyfiwNa rpwe;jJ. 
 
Rit: 
 ,J ifg;Gr; Ritia cilaJ. 
 
nra;if: 
 ,jw;F jhJ ntg;gfw;wp nra;ifAk;> Nfhioafw;wpr; nra;ifAk;> ntg;gfw;wpr; 
nra;ifAk;> ntspg;gpuNahfj;jpy; jbg;Gz;lhf;fpr; nra;ifAk; cs. 
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nghJf;Fzk;: 
 “ke;je;jh fq;fpufzp khtplr; Ruq;fz;Nzha; 
 njhe;jk; ghpehkr; R+iyfa – kpe;j 
 Tyfiwiaf; fhnyhbit NahL eiuj;j 
 gyfiwia fhzpdpak; ghH.” 
 
nghUs;: 
 ntz; gyfiwapdhy; myrk;> jhfk;> fpufzp> kfhtplr; Ruq;fs;> tpopNeha;> 
thj njhe;jk;> gytpjf; Fj;jy;> fak;> fgthjk; Kjypad ePq;Fk;.  NkYk; m[Puzk;> 
fhkhiy> fy;yPuy;> kz;zPuy; tPf;fk;> Rthrfhrk;> fhrk; Kjypa Neha;fSk; jPUk;. 
 
Rj;jp Kiw: 
 xU gyk; (35 fpuhk;) gyfiwg; nghbf;F> gj;J gyk; (350 fpuhk;) jkuj;jk; 
gor;rhw;iwf; fhiyapy; tpl;L> khiytiu nta;apypy; itj;J vLj;J kWehs; 
fhiyapYk; Gjpjhf Nkw;gb rhw;iw tpl;L ntapypy; itf;fTk;.  ,k;khjphp gjpide;J 
ehl;fs; nra;njLf;fg; gyfiw Rj;jpahFk;. 
  
 ,t;tpjk; Rj;jp nra;ag;gl;l gyfiwapdhy; nra;ag;gl;l mtpo;jq;fs;> 
gytifg;gl;l fhkhiyfs;> Njky;fs;> vhpe;J cl;zg; ngUf;fj;ij cz;lhf;Fk; 
Nej;jpug; gpzpfs; Kjypatw;iw ePf;fp cliy cukhf;Fk;. 
 
Gweil 
 thjj;ijr; NrHe;j Nkf c\;zg; gpzpapy;> tapW xU gf;fk; ,Oj;Jf; 
nfhs;Sjy;> grpapd;ik> jpkpH> gf;fk;> tapw;wb> fd;dk;> fOj;J ,t;tplq;fspy; gU 
Njhd;wpj; Jd;gj;ijf; nfhLj;jhy; ,tw;wpw;Fg; gyfiwg; gw;gj;ij kpsF ,urj;jpy; 
mDghdpj;Jf; nfhLf;f Ntz;Lk;. 
 
 gpj;jj;ijr; NrHe;j Nkf c\;zg; (jpdntd;fpw) gpzpapy; mf;fuk; 
NghypUj;jy;> tha;ePH Cwy;> the;jp> tpf;fy;> ngUe;jhfk;> tha;> cjL> 
Kftha;f;fl;il> khHGg; gs;sk;> tpuy; ,t;tplq;fspy; Gz;> gU fz;L MwhjpUj;jy; 
,tw;wpw;Fg; gyfiwg; gw;gj;ijr; Rf;F ,urj;jpy; mDghdpj;Jf; nfhLf;f Ntz;Lk;. 
 
 fgj;ijr; NrHe;j Nkf c\;zg; (nrhwp vd;w) gpzpapy; fOj;jpy; 
JHehw;wj;Jld; tpaHit fhZjy;> tapW cg;gp Nkw; Rthrk; fz;L grp> 
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jhfkpy;yhjpUj;jy;> gPdprk;Nghy; %f;fpy; ,uj;jk; tbjy;> Koq;fhy;> KJF> cr;rp 
,t;tplq;fspy; gUTk;> fl;bAk; fz;L> jiyapy; xU tpj nrhwp> Njky; Nghyj; 
Njhd;wp nrhwpe;jhy; rhk;gy; nghbiag; Nghy; J}s; cjpHe;J nfhz;bUj;jy; 
,tw;wpw;Fg; gyfiwg; gw;gj;ijj; jpg;gpyp ,urj;jpy; mDghdpj;Jf; nfhLf;f 
Ntz;Lk;. 
 
 Nkw;gb gpzpfSf;Fg; gj;jpak;- Gsp> ey;nyz;nza;> fLF> ngz; Nghfk; 
Mfpatw;iw ePf;f Ntz;Lk;. 
 
 mUe;Jk; ehssT- ,uz;L gl;rk; mUe;jp> kWgj;jpak; ,uz;L gl;rkpUf;f 
Ntz;Lk;. 
 ,ilg;gfy; rpw;Wz;b- thj Nkfj;jpw;F> Njq;fha;g; ghypy; ey;y nty;yj;ijr; 
NrHj;Jf; Fog;gpa ghy;. 
 
 gpj;j Nkfj;jpw;F>  Njq;fha;g; ghYld; rHf;fiu> NfhJik kh NrHj;Jr; 
nra;ag;gl;l gl;rzk;. 
  
 fg Nkfj;jpw;F> Njq;fha;ghypy; mhprpkh> fw;fz;L gRtpd;ghy; $l;ba (fsp) 
Njq;fha;g; Gl;lilahfr; nra;J cz;zNtz;Lk;. 
 
2.  rPtntwp eQ;rpw;Fg; gyfiwg; gw;g Ml;rp: 
 nraw;ifahfTk;> ,aw;ifahfTk; ntwpgpbj;j eha;> ehp>kdpjH> gR> vUik> 
gd;wp ,itfspdhy; cz;lhk; eQ;rpw;Fg; gyfiwg; gw;gj;ijj; jf;f Jiz 
kUe;Jld; mspj;J> Njfj;ij epiyf;fr; nra;a Ntz;Lnkd;gij 
 “eha;ehpkh dplHgRfh uhdpUsp ntwpapuz;b 
  dilap aw;if 
 aha;nraw;if topFzj;jp dhywpe;jpl;l jw;fika 
  tE$ ypj;Nj 
 ePAskh ftbntz;ik aDghdg; gbaspj;J 
  epiyf;fr; nra;Nj 
 kha;TWNj fj;ij kfp jyj;jpUj;jp ahAz;kiw 
  td;ikAs;Nshk; “. 
vd;w khGuhzr; nra;Ashywpf 
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 ,tw;Ws; nraw;if ntwp vd;gJ caHjpizahfpa khe;jHf;F kUe;jpdhy; 
tUk; ntwpAk;> m/wpidahfpa eha;;> ehp> gR> vUik> gd;wp ,itfl;Fr; RL 
fhl;bYs;s jiyNahl;by; jq;fpa ePiuf; Fbj;jyhy; cz;lhFk; ntwpAkhFk;. 
 
 ,aw;if ntwp vd;gJ NkNy nrhy;yg;gl;l m/wpiz capHfSf;Fg; 
gpwtpapNyNa cz;lhd ntwpiaAk;:> caHjpiz capuhfpa khe;jHf;F Copapdhy; 
cz;lhk; ntwpiaAk; Fwpf;Fk;. 
 
 ,t;tpUtifAs; nraw;if ntwp eQ;R jPHtJk; (rhj;jpaKk;) ,aw;if ntwp 
eQ;R jPuhjJk; (mrhj;jpaKk; ) MFk;. 
 
  
rPtntwp eQ;rpw;F gyfiwg; gw;g Ml;rp 
 eQ;Rf; fbfs;  mDghdk; czT 
1. nraw;if ntwpeha; eQ;R
,aw;if ntwpeha; eQ;R 
fy;yhypd; rhW
epyg;gid rhW 
nfhs;Sf;fQ;rp
fhuhkzpg; gUg;G fQ;rp
2. nraw;if ntwpehp eQ;R 
,aw;if ntwpehp eQ;R 
fPohney;ypr; rhW
%q;fpy; rhW 
rpWgapWf; fQ;rp
Jtuk; gUg;Gf; fQ;rp 
3. nraw;if ntwpg;gR eQ;R
,aw;if ntwpg;gR eQ;R 
ehAUtpr;rhW
ntw;wpiyr;rhW 
tufhprpf; fQ;rp
rhikahprpf; fQ;rp 
4. nraw;if ntwp vUik eQ;R
,aw;if ntwp vUik eQ;R 
td;dpapiyr;rhW
Nfhiur;rhW 
Gy;yhprpf; fQ;rp
jpidahprpf; fQ;rp 
5. nraw;if ntwpg; gd;wp eQ;R
,aw;if ntwpg; gd;wp eQ;R 
ghfypiyr;rhW
Nga;g;Gly; rhW 
%q;fpyhprpf; fQ;rp
NfhJikahprpf; fQ;rp 
6. nraw;if ntwp kdpjH eQ;R
,aw;if ntwp kdpjH eQ;R 
ehpg;gapw;wq; nfhb rhW
nrUg;gilr;rhW 
mtiug;gUg;G fQ;rp
cSe;J fQ;rp  
 
3.  fhaq;fSf;F gyfiw gw;g Ml;rp: 
1. Ks; ijj;j fhak;> khL Kl;bd fhak;> Gz; ,itfSf;Fg; gyfiwg; 
gw;gj;ijg; fpsp Kl;ilf; fUtpy; ,ioj;Jj; jlt Ntz;Lnkd;Wk;> 
2. gid kl;ilf; fUf;fpdhy; mbgl;l Gz;Zf;F> Nkw;gb gw;gj;ij Nfhop 
Kl;ilf; fUtpy; ,ioj;Jj; jltNtz;Lnkd;Wk;> 
3. fj;jp> <l;b> ghq;F ,itfspdhy; cz;lhd fhag; Gz;Zf;F> Gwh Kl;ilf; 
fUtpy; Nkw;gb kUe;;ij ,ioj;Jj; jlt Ntz;Lnkd;Wk;> 
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4. fy;yb fhak;> tpOe;j fhak; ,itfSf;Fj; jtis Kl;ilf; fUtpy; 
Nkw;fz;l kUe;ij ,ioj;Jj; jlt Ntz;Lnkd;Wk;> 
5. fij> jb> cyf;if Kjypaitfshy; cz;lhd fhaq;fSf;F fhf;if   
Kl;ilf; fUtpy; Nkw;fz;l kUe;ij ,ioj;Jj; jlt Ntz;Lnkd;Wk;. 
6. ifahy; mbgl;Lk>; efj;jhy; fps;Sg;gl;Lk;> cz;lhd fhaq;fSf;F md;wpw; 
gl;rp Kl;ilf; fUtpy; Nkw;fz;l kUe;ij ,ioj;Jj; jlt Ntz;Lnkd;Wk;. 
7. ntF tpjj;jpy; CWgl;L MwhkypUf;fpw gok; Gz;fhaq;fSf;F Mik 
Kl;ilf; fUtpy; Nkw;fz;l kUe;ij ,ioj;Jj; jlt Ntz;Lnkd;Wk; 
$wg;gl;Ls;sd. 
 
4.  gw;g kfpik 
 ,g;gw;gk;> clypypUe;J ePq;fpa td;ikiaj; jpUk;g nfhLj;J kfpo;it cz;L 
gz;Zk; vd;gjhk;. 
 
 
5.  Fl;lq;Fiw Neha;g; Gz;fSf;F 
 “Njrpg; goj;jpd; rhnwLj;Jj; 
 jpUk;gf; fyr kjdpypl;L 
 NgRk; gyfiw jhndl;Lg; 
 Ngzpf; fyr kjpypl;L 
 thr khf %bapl;Nl 
 kWfhy; utpapy; itj;jjidf; 
 $r Ntz;lh khwhehs; 
 nfhjpj;J nte;J ePwhNk”. 
 
 nte;J nfhjpj;jj; ePwjdpy; 
 kpFe;j vs;sp nda;tpl;Lr; 
 rpe;ij kfpof; Fioj;njLj;Jj; 
 jpUk;gg; Gz;NkypLtPNuy; 
 te;j Fl;lq; FiwNehAk; 
 twpa Gz;Z khwptpLk; 
 rpe;ij kpfNt rptdhiz 
 jPU nkd;whH jpUKdpNa” 
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gyfiw NrUk; kUe;Jfs;: 
1. gyfiwg; gw;gk; :5 
Rj;jp nra;j gyfiw - gyk;  3 (105 fpuhk;)> 
J}a;ik nra;j urk;  - nry;yj;jf;f msT>  
vYkpr;rk;gor;rhW  - nry;yj;jf;f msT>  
,ye;ijapiyr;rhW  - nry;yj;jf;f msT 
 nra;Kiw: gyfiwia fy;tj;jpypl;L nghbj;J ,ye;ijr; rhw;iwr; 
rpWfr; rpWfthHj;J ,uz;L rhkk; (6 kzp) miuj;J tpy;iy nra;JyHj;jp 
mfypy; itj;J Nkyfy; %b %d;W rPiy kz; nra;JyHj;jp E}w;iwk;gJ gyk; 
(5250 fpuhk;) twl;bapw; Glkpl;lhwpd gpd;ndLf;fg; gw;gkhapUf;Fk;.  ,e;jg; 
gw;gk; 5 – gq;F> J}a;ik nra;j urk; 1 gq;F ,t;tpuz;ilAq; fy;tj;jpw; 
NrHj;jiuj;J vYkpr;rk; gor;rhw;iwr; rpWfr; rpWf thHj;J 4- rhkk; (12 kzp) 
miuj;J tpy;iy nra;JyHj;jp mfypypl;L Nkyfy; %b 5 rPiy kz; 
nra;JyHj;jp> E}w;iwk;gJ gyk; (5250 fpuhk;) tul;bapy; Glkpl;lhwpd 
gpd;ndLf;fg; gw;gkhapUf;Fk;> ,urj;jpndil epw;fhJ. Mdhy; mjd; 
rj;ijf; nfhLj;Jtpl;L Xbg; NghFk;. 
 msT:  2 Kjy; 4 Fd;wpkzp vil 
 JizkUe;J : Njd;> nea;> ntz;nza; KjypaitfshFk; 
  
jPUk; Neha;fs;:  
  
Ruk;> gpuNkfk;> tapw;WNeha;> tpf;fy;> ,Uky;> epzf;fopr;ry;> %yk; Kjypa gy 
Neha;fs; jPUk;.  ,jidj; jFe;j JizkUe;Jfspy; gpj;jrk;;ge;jkhd vy;yh 
Neha;fSf;Fk; cgNahfpf;fyhk;. 
 
2. Rj;jp nra;j gyfiw – 1 gyk; 
fQ;rh ,iy - 7 gyk; 
 gyfiwia fQ;rh ,iyahy; ftrk; nra;J> mjd; Nky; 3 rPiykz; 
nra;J 1f[Glkpl;L Mwpd gpd; vLf;f gw;gkhFk;. 
 msT : 1-2 Fd;wp 
 Jiz kUe;J – Njd;> nea;> ntz;nza;> 
 jPUk; Neha;fs; : ngUkstpy; gpj;j rk;ge;jkhd Neha;fs;> gpj;j Ruk;> 
ehl;gl;l Ruk;> vYk;GUf;fp5 
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3. eLj;jukhd gyfiw- 8 
,jid xU gPq;fhd; ghj;jpuj;jpy; Nghl;L 1 Mohf;F vYkpr;rk;gor;rhW tpl;L 
1 ehs; itf;f gyfiw vy;yhk; fiue;J NghFk;.  gpwF jphp Nghl;L ePiu 
tbj;Jf; nfhs;sTk;.  ,e;j ePiuf; Fbj;J tuTk;. 
jPUk; Neha;fs; : gpj;j Nkfk;> %j;jpu fphpr;ruk;> ePnuhpr;ry;> ePuilg;G> ePHf;fl;L 
jPUk; 5 
 
4. gyfiwia mfypy; itj;J Nky; mfy; %b nfhy;yd; ciyapy; itj;J mfy; 
rptf;f Cjp vLj;J Mw itj;J vLf;f gyfiw gw;gkhFk;.  ,jid 1 
Mohf;F vYkpr;rk;gor;rhw;wpy; Nghl;L fyf;fp jphpNghl;L njsptpWj;J 
cgNahfpf;fyhk;. 
jPUk; Neha;fs;: ePnuhpr;ry;> ePuilg;G> gpj;j rk;ge;jkhd Neha;fs;> 
%j;jpuf;fphpr;ruk;> gpuNkfk;.5 
 
5. 1 gyk; Rj;jp nra;j gyfiwia vLj;J fPOs;s gl;baypy; Fwpj;j Kiwg;gb 
miuj;J cyHj;jpg; GlkplTk;.  miuf;Fk; xt;nthU ehSk;> Fwpj;j vil 
Gjpa rhw;iw cgNahfpf;fTk;.  tpy;iyia cyHj;j gfypy; R+hpa xspapy; 
itg;gJ Nghy ,utpy; gdpapYk; itf;fTk;. 
 
rhw;wpd; ngaH rhw;wpd; 
msT gyk;
miuf;Fk; 
ehs; 
tpy;iy 
cyHj;Jk; 
ehs; 
ftrk; 
cyHj;Jk; 
ehs; 
Glk; twl;b
RuGd;id r%yr;rhW 4 6 5 1 36
rpj;jpu%y r%yr;rhW 4 5 4 1 30
fy;yhy; r%yr;rhW 4 4 3 1 24
fhl;Lky;ypif 
r%yr;rhW 
3 3 2 1 18
ePNyhw;gy r%yr;rhW 2 2 1 1 12
re;jdf;Fok;G njspePh 1 1 1 1 6
 
msT - fliy 1/5 
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jPUk;Neha;fs;: 
nts;isr; rHf;fiuapy; nfhLf;f – gpj;jNeha;> mijr;rhHe;J tug;gl;lgy;iy 
Neha;> ngUtapW> gPdprk;> tpf;fy; Nghk;. 
gyfiw NrUk; gpw kUe;Jfs;: 
1. ,uh[Nyhf ehjur gw;gk;10 
2.  Jj;j nre;J}uk;10 
3.  tp\;D rf;fu khj;jpiu13 
 
 
vYkpr;ir 
NtWngaHfs;:17 
 rk;gPuk;> Njrpagok;> ,uhrfdp;> mkpHjgiy  vd;gd. 
Rit: 
 Gspg;G 
jd;ik: 
 ntg;gk; 
gphpT: 
 fhHg;G 
nra;if: 
 FspHr;rpAz;lhf;fp 
nghJFzk;: 
 jPnjY kpr;rq;fha; NlHKj;Njh lj;ijAKs; 
 thjfg R+iyiaAk; khnfhba – rhjpnaDQ; 
     rj;jpFd; kj;ijAKs; jq;fkUe; jpl;lj;ijAk; 
     gpj;jntbg;ig Ae;jzpf;Fk; NgR 
     (mfj;jpaH Fzthflk;) 
 vYkpr;rq;fha; Kf;Fw;wk;> R+iy> the;jp> Fd;kk;> ,LkUe;J> moy; 
,itfisg; Nghf;Fk;. 
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 NkYk; ke;jphp vdf;$Wk; jPf;Fw;wj;ijj; jzpf;Fk;> je;jphpahfpa Iaj;jpw;F 
md;gd;NghypUe;J mdiy tsHf;Fk;> ,jid 
 ke;jphpf;F ke;jphpaha; kd;dDf;F kd;dnddj; 
 je;jphpf;F kpj;jpud;Nghw; rhUNk – Ke;jtU 
 fk;gPU kha;r; ruf;fpd; nfz;zpakha; thflHf;Fr; 
 rk;gPu khnkYkpr; ir 
      (Njud; fhg;gpak;) 
vd;Dk; nra;Ashy; mwpayhk; 
 Ruj;jpy; cz;lhFk; the;jpfl;Fk;> tha;Fkl;lYf;Fk; ,g;gourj;jhy; 
nra;ag;gLk; rhjprk;gPuf;Fok;G ew;gad; jUk;. NkYk; gpj;j Neha;fSf;F gad;gLk; 
mNdf kUe;Jfspy; ,jd; rhW NrHf;fg;gLfpwJ.  
  
 vYkpr;rk; gok; fw;g kUe;Jfspy; xd;W.  ,jid urKk; CWfhAkhf 
fw;gKiwahfg; gj;jpaj;JlNd 6 khjk; cl;nfhs;s eiu> jpiu khWk;.  gpbg;G> 
ngUtapW> gf;f R+iy> Klk;> ntwp> kaf;fk;> kdr;NrhHT vd;gitfSk; mbNahL 
ePq;Fk;.  ,jid 
 Nfhzj; JisAq; FwpAisAq; nfhf;fhfpg; 
 Nfhzj; JisAq; FUisNghw; - Nfhzr; 
 rlkjpAz; khwhkw; rk;gPuf; fw;gQ; 
 rlkjpAz; khwhkw; rz;. 
     (Njud; akf ntz;gh) 
vd;Dk; nra;Ashy; mwpayhk;. 
 
 
 
 
 
 
. 
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ZOOLOGICAL ASPECTS 
 
CYPRAEA MONETA, Linn 
 
CLASSIFICATION: 
 
Kingdom : Animalia 
 
Phylum : Mollusca 
 
Class  : Gastropoda 
 
Order  : Sorbeoconcha 
 
Family  : Cypraeidae 
 
Genus  : Cypraea 
 
Species : moneta 
 
 
VERNACULAR NAMES:25 
 
Tamil  : Chozhi, Palagarai 
 
English : Porceleneous Shells, Cowry 
 
Sanskrit : Varatika, Varataka 
 
Arabic  : Sadaf 
 
Hindi  : Cowrie, Kowdi 
 
Malayalam : Kavati 
 
Kannada : Kavadi 
 
Bengali : Beya 
 
Gujarathi : Codi 
 
 
HABITAT:25 
 
The cowry lives in inter tidal rocky areas. It can be found on and under rocks in 
shallow water and on exposed reefs at low tide. It feeds an algae and marine vegetation 
growing on loose rocks and pieces of dead coral. 
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SHELL DESCRIPTION: 
 
Small, Convolute, Glossy shells of variegated colours of oblong oval shape varying in 
size from a tamarind seed to an almond. 
The upper face is smooth shining and convex. Base is compressed with a cleft in the 
center which runs longitudinally. The margin of the cleft is serrated on one side and 
depressed on the other. 
The fresh shells consist of a cellular gelatinous tissue filled with Calcareous matter 
(earthy salts). They are insoluble in water, soluble in hydrochloric acid with effervescence. 
 They contain phosphate, fluoride and carbonate of calcium;> magnesium;> 
phosphate;> manganese and sodium chloride. 
 
DISTRIBUTION: 
 
 The entire tropical Indian and  Pacific oceans from East Africa to Central America 
including Northern Australia. 
 
COMPARISION: 
 
                Cypraea moneta occasionally has an orange ring on the dorsum similar to Cypraea 
annulus. But it is distinguished by its heavy margin. Juvenile specimens of the 2 species are 
difficult to separate. 
 
 
REMARKS: 
 
              This is the well known money cowry which was used for currency in some parts of 
Africa, Asia and Oceania. It is an extremely common shell in its tropical range. 
 
             Last century vast quantities were collected on the east coast of Africa and shipped to 
West Africa, where the shell does not occur naturally. In the year 1867 alone, 67,000 
hundred weight passed through the port of Lagos., to be used as payment for oil seed, Under 
this pressure rapidly devalued as a currency in the latter part of Nineteenth century. 
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MEDICINAL USES:25 
 
Cowri Bhasma is pungently bitter also alterative and expectorant. It is recommended 
in Dyspepsia, Jaundice, Enlarged Spleen & Liver, Asthma and cough. 
 The ash is given internally in scalding and gonorrhoea. It is externally used as a 
caustic as various forms of ointments. 
 Shula Gaja Kesari is a compound pill made of purified shell, mercury borax, rock-
salt, asofoetida and Caruli seeds all in equal parts mixed and reduced to a pill mass with the 
aid of the juice of betel leaves. Dose is 3-5 grains useful in Colic and pains of intestine. 
 
 
 
BOTANICAL ASPECT 
Citrus limon (linn) Burm.F 
 
CLASSIFICATION: 
 
Class  : Dicotyledons 
 
Subclass : Polypetalae 
 
Series  : Disciflorae 
 
Family  : Rutaceae 
 
Genus  : Citrus 
 
Species : limon 
 
 
VERNACULAR NAMES:19 
 
Tamil  : Elumichai 
 
Sanskrit : Jambira, Nimbu Phala 
 
English : Lemon 
 
Telugu  : Nimma 
 
Unani  : Leemu, Baraa neebu 
 
 93 
 
 
HABITAT:20 
 
Tropical parts of India, commonly found in Kumaon, northern and central India. 
 
HABIT:20 
 
A lemon tree can grow up to 10 metres, but they are usually smaller. The branches are 
thorny and form an open crown. The leaves are green shiny and elliptical. Flowers are white 
on outside with a violet streaked interior and have a strong fragrance. 
The citrus fruit is a special kind of berry called Hesperidium. Hesperidium is almost 
unique to the genus of citrus, oblong or globose in shape but of various sizes.  
The Hesperidium has a thick oil-gland dotted rind, green when unripe turning yellow 
as the fruit ripens, a thin, papery white albido on the inside of the rind and a many chambered 
endocarp with a few seeds in each chamber. From the inner walls of each chamber, grow 
transverse juice-called hairs, which constitute the edible part of the fruit. 
 
 
CHEMICAL CONSTITUENTS:19 
 
Limonene is a principal constituent of essential oil. Others are Citronellal, n-nonamel, 
n-decanal, n-dodecanol, linalyl-acetate, geranyl acetate, citronellyl acetate, methyl anthrailate 
and lipophilic flavanoids including sinesetin and furocoumarins.  
 
The chief flavanoids are bitter neohesperidine naringin and neohesperidin, dihydro 
chalcones, hesperidine and rutin. 
 
It also contains glycosyl apigenin, B-caryophyllene, limocitrol, limocitrin, abscisic acid, 
gibberellic acid, abscisinII, auxin and isorhamnetin. 
 
Fresh lemon juice contains minerals such as Zinc, Selenium, Manganese, Magnesium, 
Molybdenum, Iron, Copper, Phosporus, Sodium, Potassium Fluoride, Iodine, Chromium, 
Chloride and Calcium. It also contains vitamin A, pantothenic acid, Thiamin, niacin, 
riboflavin, vitamin B6, vitamin B12, biotin, vitamin C, E and K. 
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MATERIALS AND METHODS 
 
COLLECTION OF THE TEST DRUG 
 Palagarai was collected from the indigenous raw drug stores Thambaram.   
 
gyfiw Rj;jp 
 gyfiwia xU ghj;jpuj;jpy; Nghl;L mjd; kPJ vYkpr;rk;gor; rhw;iw tpl 
Ntz;Lk;.  ,r;rhwhdJ gyfiwf;F Nky; 1 mq;Fyk; ,Ue;jhy; NghJkhdJ 
mjhtJ 1 mq;Fyk; cs;Ns Mo;e;jpUf;f Ntz;baJ. ntapypy;; itj;J rhnwy;yhk; 
Rz;bd gpd;G jz;zPH tpl;L Rj;jkhf fOtp vLj;J ntapypy; cyHj;jp itj;Jf; 
nfhs;tNj Rj;jpahFk;. 
 
PREPARATION OF THE DRUG: 
 105 grms of palagari was put in a mud vessel and soaked with lime juice and sun – 
dried for 2 hours and covered using a mud cap (Agal).  Then the mud cap and the vessel was 
covered using 7 layers of clay pasted clothes (seelai).  Once dried it was calcined by using 
30–40  cow dung  cakes.  After heat gets settled, the mud vessel was un covered and  
calcined oxide was noticed.  The calcined oxide was then replaced into a different vessel,  
powdered well with the help of stone mortar and preserved in a air tight vessel. 
 
INTENDED THERAPEUTIC DOSE & DURATION 
  130 mg , b.d. with butter after food for 24 days 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
BIO CHEMICAL ANALYSIS 
 
CHEMICAL ANALYSIS OF PALAGARI PARPAM 
 
SI.NO EXPERIMENT  OBSERVATION  INFERENCE  
1. Appearance of the sample   Dark green colour   
2. Solubility: 
a. A little of the sample is shaken 
well with distilled water 
b.  A  little of the sample is shaken 
well with con Hcl/ con H2SO4 
 
Sparingly soluble 
 
 
Completely soluble 
 
 
 
 
Absence of silicate 
3. Action Of Heat: 
  A small amount of the sample is 
taken in a dry test tube and heated 
gently at first and then strongly 
 
White fumes gas evolved 
No brown fumes 
 
Presence of carbonate’ 
Absence of Nitrate 
4. Flame Test: 
A small amount of the sample is 
made in to a paste with con. Hcl in a 
watch glass and introduced into 
nonluminous part of the Bunsen 
flame 
 
 
Bluish green colour 
flame is not appeared 
 
 
Absence of Copper 
5. Ash Test: 
   A filter paper is soaked into a 
mixture of sample and add cobalt 
nitrate solution and introduced into 
the Bunsen flame and ignited  
 
Yellow colour flame not 
appeared 
 
 
 
Absence of sodium 
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PREPARATION OF EXTRACT 
 5 gm of Palagarai parpam is weighed accurately and placed in a 250 ml clean beaker 
and added with 50ml of distilled water. Then it is boiled well for about 10 minutes Then it is 
cooled and filtered in a 100ml volumetric flask and made up to 100ml with distilled water. 
SL NO. EXPERIMENT OBSERVATION INFERENCE 
I Test For Acid Radicals   
1. Test For Sulphate: 
 a. 2 ml of the above prepared extract 
is taken in a test tube, to this, add 2ml 
of 4% ammonium oxalate solution 
 
No Cloudy 
appearance 
present  
 
Absence of solphate. 
 b. 2ml of the above prepared extract is 
added with 20ml of dil, Hcl is added 
until the effervescence ceases off. 
Then 2ml of Barium chloride solution 
is added.  
No white 
precipitate 
insoluble is con, 
HCL 
Absence of sulphate  
2. Test  For Chloride: 
   2ml of the above prepared extract is 
added with dil. HNO3 till the 
effervescence ceases. Then 2ml of 
silver nitrate solution is added  
Cloudy 
appearance  
Presence of Chloride  
3. Test For Phosphate: 
   2ml of the extract is treated with 
2ml of ammonium molybdate solution 
and 2ml of con.HNO3 
 
No cloudy yellow 
appearance  
 
Absence of Phosphate 
4. Test For Carbonate: 
    2ml of the extract is treated with 
2ml of magnesium sulphate solution  
 
Cloudy 
appearance  
 
Presence of carbonate  
5. Test For Nitrate: 
     1gm of the substance is heated 
with copper turning and concentrated 
H2SO4 and viewed the test tube 
vertically down 
 
No characteristic 
changes 
 
 
Absence of Nitrate  
6. Test For Sulphide: 
    1gm of the substance is treated with 
2ml of con. Hcl 
 
Colourless, no 
rotten egg 
smelling gas  
 
Absence of sulphide  
7. Test For Fluoride & Oxalate: 
   2ml of extract is added with 2ml of 
dil acetic acid and 2ml of calcium 
chloride solution and heated  
 
No cloudy 
appearance  
 
Absence of fluoride and 
oxalate  
8. Test For Nitrite: 
   3 drops of the extract is placed on a 
filter paper, on that 2drops of acetic 
acid and 2 drops of benzidine solution 
is placed. 
 
No reaction  
 
Absence of Nitrite  
9. Test For Borate:   
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   2 Pinches  of the substance is made 
into paste by using sulphuric acid and 
alcohol (95%) and introduced into the 
blue flame  
No Bluish green 
colour flame 
appeared  
Absence of Borate  
II Test For Basic Radicals    
 
1. 
 
Test For Lead  
   2ml of the extract is added with 2ml 
of potassium iodide solution  
 
No yellow 
precipitate  
 
Absence of lead 
2. Test For Copper: 
a. One pinch of substance is made in
b. to paste with con. Hcl in a  watch 
glass and introduced into the non-
luminous part of the Bunsen 
flame.  
c. 2 ml of extract is added with 
excess of ammonia solution  
 
No blue flame  
 
 
 
 
No blue 
precipitate  
 
Absence of copper 
 
 
 
 
 
Absence of copper  
3. Test For Aluminium : 
  To  the 2ml of the extract sodium 
hydroxide is added in drops to excess  
 
No characteristic 
changes  
 
Absence of aluminium  
4. Test For Iron: 
a. To the 2ml of extract add 2ml of 
ammonium thiocyanate solution. 
b. To the 2ml extract add 2ml 
ammonium thiocynate solution 
and 2ml of con HNO3 is added  
 
Blood red colour 
is not appeared  
 
No red colour 
developed 
 
Absence of Iron  
 
 
Absence of Iron  
5. Test For Zinc: 
    To 2ml of the extract sodium 
hydroxide solution is added in drops 
to excess  
 
White precipitate 
obtained  
 
Presence of Zinc 
6. Test For Calcium: 
   2ml of the extract is added with 2ml 
of 4% ammonium oxalate solution  
 
Cloudy 
appearance,  white 
precipitate is 
obtained  
 
Presence of calcium  
7. Test For Magnesium: 
  To 2ml of extract sodium hydroxide 
solution is added in drops to excess  
 
 
White precipitate 
is obtained  
 
Presence of magnesium  
8. Test For Ammonium: 
   To 2ml of extract few ml of 
Nessler’s reagent and excess of 
sodium hydroxide solution are added  
 
Mild reddish 
brown colour is 
not appeared  
 
Absence of ammonium  
9. Test For Potassium: 
  A pinch of substance is treated with 
2ml of sodium nitrate solution and 
then treated with 2ml if cobalt nitrate 
in 30% glacial acetic acid  
 
 
 
Yellowish 
precipitate is not 
obtained  
 
 
Absence of Potassium  
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10. Test For Sodium: 
  2 Pinches of the substance is made 
into paste by using  Hcl and 
introduced in to the blue flame, of 
Bunsen burner 
 
Yellow colour 
flame not 
appeared  
 
Absence of Sodium  
11. Test For Mercury: 
   2ml of the extract is treated with 
2ml of sodium hydroxide solution  
 
No yellow 
precipitate is 
obtained  
 
Absence of Mercury  
12. Test For Arsenic: 
   2ml of extract is treated with 2ml of  
silver nitrate solution  
 
 
No brownish red 
precipitate is 
obtained  
 
Absence of Arsenic  
III Miscellaneous:   
1. Test For Starch: 
  2ml of extract is treated with weak 
iodine solution  
 
No blue colour 
developed  
 
Absence of Starch  
2. 
 
 
 
 
Test For Reducing Sugar: 
  5ml of Benedicts qualitative solution 
is taken in a test tube and allowed to 
boil for 2 minutes and added 8 to 10 
drops of the extract and  again boil it 
for 2 minutes.  The colour changes are 
noted 
 
 
No colour 
Changes  
 
 
Absence of Reducing 
sugar 
3. 
Test For The Alkaloids: 
a.  2ml of the extract is treated with   
  2ml of potassium iodide solution.  
b.    2ml of extract is treated with 2ml 
of picric acid.  
 
c.   2ml of the extract is treated with 
2ml of phosphotungstic acid  
 
 
No red colour 
develops  
 
No yellow colour 
develops  
 
No white 
precipitate 
obtained  
 
 
Absence of alkaloid  
 
 
Absence of alkaloid  
 
 
Absence of alkaloid 
4. Test For Tannic Acid: 
   2ml of extract is treated with 2ml of 
ferric chloride solution  
 
No Black 
precipitate is 
obtained  
 
Absence of Tannic acid  
5. Test For Unsaturated  Compound:   
To the 2ml of extract 2ml of 
potassium permanganate solution is 
added  
 
Potassium 
permanganate is 
not decolourised  
 
Absence of unsaturated 
compound  
6. Test For Amino Acid: 
  2drops of the extract is placed on 
filter paper and dried well 
  
 
No Violet colour 
obtained  
 
Absence of amino acid  
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7. Test For Albumin: 
   2ml of the extract is added with 2ml 
of ESBOCH’S reagent  
 
 
 
No yellow colour 
precipitate is 
formed  
 
Absence of albumin  
8. 
Test For Type of Compound: 
 2ml of the extract is treated with 2ml 
of ferric chloride solution  
 
 
 
i No green 
colour 
developed 
 
ii No red 
colour 
developed  
 
 
 
iii No Violet 
colour 
developed  
 
 
iv No blue  
colour 
developed 
 
 
v No Black 
colour 
developed  
 
 
 
i) Absence of oxyquinole 
epinephrine and 
pyrocatechol  
 
ii)Anti prine Aliphtic 
amino acids and mecinic 
acid are absent  
 
  
 
iii)Apo morphine 
salicylate and resorcinol 
are absent  
 
 
iv) Morphine, Phenol, 
cresol and hydro-quinone 
and  absent.  
 
 
v)Absence of Tannin  
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PHYSICAL PROPERTIES 
 
Loss on Drying  
  5gms of material is heated in a hot oven at 105˚C to constant weight. The percentage 
of loss of weight was calculated.  
 
Determination of ash Value 
 Weight accurately 2-3gms of sample in tarred platinum or silica dish and incinerate at 
a temperature not exceeding 450˚C until free from carbon, cool and weigh. Calculate the 
percentage of ash with reference to the air dried drug.  
 
Acid Insoluble ash 
 Boil the ash for 5 minutes with 25ml of 1:1 dilute HCl. Collected the insoluble matter 
in Gooch- crucible on an ash less filter paper, wash with hot water and ignite, cool in a 
dessicator and  weight. Calculate the percentage of acid insoluble ash with reference to the 
air dried drug.  
 
Water Soluble ash 
 To the Gooch crucible containing the total ash, and 25ml of water and boil for 5 
minutes. Collect the insoluble matter in a sintered glass crucible or on ash less filter paper. 
Wash with hot water and ignite in a crucible for 15 minutes at a temperature not exceeding 
450˚C. Subtract the weight of the insoluble matter from the weight of the ash; the difference 
of weight represents the water soluble ash. Calculate the percentage of water soluble ash 
reference to the air dried drug.  
Alkalinity of water soluble ash  
 5gms converted to ash, boiled with water, filtered, Filtrate was titrated against  0.1N 
of HCl  using phenolphthalein as an indicator.  
 Alkalinity of water  soluble ash=X x of acid / 0.1 x  W. 
 
 X= Titre value  
 
 W= Weight of the materials taken 
 
 Alkalinity is given as ml of 0.1 N  of HCL equal to 1gm 
pH 
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5gms  of   Palagarai Parpam is weighed accurately and placed in clear 100ml beaker. A 
few drops of Aquaregia was added and evaporated by heating for few minutes. After cooling 
the content, 50ml of distilled water is added to it and dissolved well. Wait for 30 minutes and 
then apply into PH matter at standard buffer solution at 4.0, 7.0 and 9.2. 
 
 
 
PHARMACOLOGICAL STUDY 
 
ACUTE TOXICITY STUDIES 
 
Honey was used as vehicle. Starting dose was 5mg/kg, and the subsequent doses used 
were 10, 50, 100, 250, 500, 1000 2000 and 4000mg/kg p.o. Palagarai Parpam suspended in 
honey was administered to the groups of wistar rats in a single oral dose by gavage using a 
feeding needle. The control group received an equal volume of the honey vehicle. Six 
females and males were used for each dosage level. The principles of laboratory animal care 
were followed and the Department’s ethical comittee approved the use of the animals and the 
study design. Observations were made and recorded systematically 1, 2, 4 and 24 h after 
substance administration. The visual observations included skin changes, mobility, and 
aggressiveness, sensitivity to sound and pain, as well as respiratory movements. They were 
deprived of food, but not water 16–18 h prior to the administration of the test suspension. 
Finally, the number of survivors was noted after 24 h and these animals were then maintained 
for a further 13 days and observations made daily. The toxicological effect was assessed on 
the basis of mortality, which was expressed as LD50.  
 
ANTIMICROBIAL ACTIVITY OF PALAGARAI PARPAM 
Aim: 
The present study was designed to assess the antimicrobial property of Palagarai 
Parpam.  
MATERIALS AND METHODS 
Test organisms 
The following microorganisms were used for the study. In the present study, the 
antimicrobial activity of the Palagarai Parpam against Escherichia coli, Klebsiella species, 
Proteaus vulgaris, Trichomonas, Candida albicans and Staphylococcus aureus was carried 
out.  These micro-organisms were obtained from the laboratory stock of the Department of 
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Pharmaceutical biotechnology, Vel’s college, Pallavaram. They were maintained on agar 
slants at 4oC in the refrigerator.  
Drugs and Microbiological Media 
Palagarai Parpam (1mg/ml) stock solution was used. Nutrient broth and nutrient 
Agar and Sabouraud Dextrose Agar. 
Preparation of plates for susceptibility tests 
 The agar-well diffusion method, suitably modified was adopted for the susceptibility 
studies. Inocula of the test organisms obtained were prepared by growing each pure isolate in 
nutrient broth overnight 37oC. The overnight broth culture was, subcultured in fresh nutrient 
broth and grown for 3 hours, to obtain log phase culture. This was matched with 
MacFarland’s turbidity standard to give approximately 108cfu/ml. Aliquots of 0.1, 0.2, 0.3ml 
was used to seed a molten nutrient agar medium, which was cooled to 45oC to obtain 
approximately 106cfu/ml. This was poured into the sterile petridishes and used for the 
investigations. Candidia albicans was grown on sabouraud 4 % glucose agar and suspension 
in 1/4 strength Ringers solution was used to prepare the seeded Sabourand 4 % Dextrose agar 
plates.  
The Palagarai Parpam stock solution was reconstituted with sterile distilled water 
and stock concentration of 1mg/ml or 100mg/ml was made. The Palagarai Parpam was 
tested at a concentration of 25mg/ml. 10, 20, 30µl of this concentration was delivered into 
wells (4mm in diameter) bored into the already seeded nutrient agar plates. One hundred 
microlitres of cell suspension from the standard inoculum were plated and 6 mm wells were 
drilled into the agar. 10-30 microlitres of test drug prepared using DMSO/H2O (25 % v/v) 
were dropped into the wells. The DMSO/H2O solution served as the negative control. The 
plates were incubated under microaerophilic conditions at 37 °C for 72 hours. Test drug that 
showed a diameter of inhibition 8 mm were considered to be active. The active drugs were 
further diluted serially using sterile DMSO/H2O (25 % v/v) to obtain 3 serially two-fold 
decreasing concentrations which were re-tested in triplicate and the results expressed as a 
mean diameter of inhibition zone.  
nts;is (ntl;il> gpuNkfk;) 
NtWngaH:   
ntl;il Neha;> gpukpak; 
,ay;G:   
 103 
 
rpWePH ,wq;Ftjw;F Kd;Ngh my;yJ gpd;Ngh ntz;zpwj;Jld; rPo;Nghy; 
,optJk;> ePHg;Gioapy; vhpr;riyAk; fLg;igAk; cz;lhf;Fjyhk;. 
Kw;Fwpfs;: 
,e;NehAw;wthplk; fytp nra;j rpy (,uz;L %d;W) ehl;fs; nrd;wgpd;> 
Fwpapy; eik> ePHg;Gioapy; vhpr;ry; Mfpa Fwpfisf; fhl;b> ePhpwq;Fk;NghJ rPo; 
fye;jhw; Nghypwq;fp> E}y; njhq;FtJ NghYk; ntz;ilf;fha; fOtpa ePHNghYk; 
ntspahFk;. 
Neha;tUk;top: 
 msT fle;j fytpahYk;> ,e;NehAw;Nwhhplk; $LtjhYk; cz;lhFk;.  NkYk;> 
Nahfj;jpy; epiyj;J %yf;fdiy vOk;Gk; NghJk; ,e;Neha; gpwf;Fk; vd;gH rpyH. 
Neha; vz;: 
 “ciuj;jpl;Nld; gpukpnad;w Nehiaj; jhNd 
 cj;jkNd ,Ugj; njhd;whq; fz;lhNa.”    
nts;is 21 tifg;gLk;> mit 
tsp> moy;> Ia> tspmoy;> moiya> Kf;Fw;w> fl;b> ePh;> je;jp> FUjp> rPo;> xOf;F> 
kQ;rs;> fphpr;ruk;> fug;ghd;> fy;> E}y;> ePr;R> kypdk;> ,dpg;G> Gz; nts;is Mfpait 
MFk;. 
nghJf;FwpFzq;fs;: 
 ntg;g nghUis Al;nfhs;StjhYk; Nahf epiyapUj;jyhYk; fPo;f; 
fdnyOk;gp> moy; Fw;wj;ijf; nfLj;J ePHg;Gio> ePHg;ig ,itfspy; jhgpjj;ij 
cz;L gz;zpg; Gz;gLj;jp mjpdpd;W nts;is apopar; nra;Ak;. 
 ehs; nry;yr; nry;y rPo; fbdg;gLtJld; mjpf mstpy; kQ;rs; epwj;Jld; 
ntspahFk;.  md;wpAk;> ,Lg;G> KJF> Jil Kjypad NehFk;.  rpyNtisfspy; 
RuKq;fhZk;.  ntg;gkpFjpahy; kyk; ntspg;gLjiyj; jLf;Fk; grpAkpuhJ.  kpFe;j 
ntg;gj;jpdstha; ePHg;Gio neUg;Gg;Nghy; vhpe;J> Gz;gl;Lf; FUjp kpFjpaha; 
,opAk;.  mg;NghJ ePhpwq;f KbahJ capH Nghfpd;wJ Nghy typf;Fk;.  ,jidj; 
jhq;f Kbahj rpyH kpf tUe;JtH. 
Fw;w Kjypa NtWghLfs;: 
 czT> nray; Mfpatw;why;> moy; Fw;wk; jd;dstpy; kpFe;J> 
fPo;Nehf;Ff;fhiyf; Nflilar; nra;J> jdf;Fj; Jizaha;g; guTfhiyAk; nfLj;J> 
rpWePHj;JisapYk; vUthapYk; fdiy %l;b> FUjpiaf; Nflilar; nra;Ak;.  
,jdhy; grpj;jPapd; td;ik ,oe;J> cly; td;ikAk; Fiwe;J kdKQ; NrhHtilAk;. 
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MODERN ASPECT 
 
LEUCORRHOEA 
Leucorrhoea, vaginal discharge is a universal problem of all women. No body escapes from 
this illness. Female genitals are very much prone to infections since they are moist, more 
sweaty and covered. The white vaginal discharge with foul  smell makes it embarrassing to 
get into social gatherings and even engage in personal affairs. The affected women need 
reassurance, prevention of infection and some counseling as they usually have abnormal 
psychosomatic scores. Most secretions are  regarding life style physiological and warrant no 
medical interventions. But it is significant if it is blood stained, profuse, foul smelling or with 
changes in its colour. Usually the normal secretions are slimy and slightly sticky. It is 
something like nasal secretion. Normally the quantity of vaginal secretions varies throughout 
the menstrual cycle, peaking at ovulation and also increasing when under emotional stress. 
 
CLSSIFICATION: 
 Leucorrhoea is mainly classified into two types: 
Physiological leucorrhoea: 
 It is an excessive discharge or secretions of a normal vagina. They are slimy in nature 
and generally occur among teenaged girls due to hormonal imbalance  during puberty, at the 
time of ovulation period of the menstrual cycle, before periods, etc. In case of adults, in 
addition to the ovulation time and before periods, it occurs also during early days of 
pregnancy and during sexual excitement. Generally, no medication is required in this kind of 
discharge.  
Pathological leucorrhoea: 
 It is a discharge occurring due to disease or malfunction of the female reproductive 
tract. It needs immediate attention, cleanliness and treatment. Ignoring pathological 
leucorrhoea may lead to serious problems like loss of fertility or even removal of uterus. The  
nature of discharge varies from slimy to thick bloody discharge with foul smell. This 
condition is commonly present both in case of vaginitis or  cervicitis.  
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Causes of Leucorrhoea: 
1.Infections: 
From Fungus:  
 Candida albicans can easily flourish in moist circumstances and is commonly 
promoted by synthetic undergarments and poor hygienic condition.  
 
From Parasites: 
 Protozoa – Trichomonas  vaginalis causes the Trichomoniasis which spreads usually 
through sexual intercourse and moist clothes.  
 
From Bacteria: 
 Gardnerella  vaginalis and chlamydia are the prime causes in bacterial infections. 
Also, it is frequently seen in venereal disease like gonorrhoea, syphilis and AIDS.  
 
2.Injury: 
 Injury to the vagina or cervix or wound during childbirth, abortion, or excessive 
sexual indulgence can cause erosions and infections with discharges. 
 
3.Poor hygienic conditions: 
 Non hygienic measures, especially during periods, can create infection and cause 
leucorrhoea.  
 
4.Diabetes and anaemia: 
 May provoke infections due to weakened immunity among many females.  
 
5.Local infection: 
 Spread of infection from adjacent urinary tract (UTI) or alimentary tract (worms) 
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6.Irritation of IUCD: 
 If  irritation persists at IUCD, (Intra uterine contraceptive device) it can cause pain 
and discharges.  
 
7.Sprays  and jellies: 
 Which are used by males for provoking sexual act and jellies and drugs taken by 
females to kill sperms to avoid conception can also irritate and initiate the infective process. 
 Symptoms of leucorrhoea: 
 Mostly there won’t be any symptom other than discharge. Discharge may be slimy, 
viscid to dark coloured  or even bloody with a foul smell. In some cases, the accompanying 
symptoms are: 
 Lower abdominal pain 
 Painful sexual act 
 Backache and pain in the leg, especially thigh and calf muscles 
 Intense itching with oedema of vagina 
 Soreness and burning in the genital tract 
 Burning urination and frequent urge to pass very little urine 
 Irritability and lack of concentration in work due to consciousness of discharges 
 Digestive disturbances like diarrhoea or vomiting  
 General tiredness due to loss of vital fluids as discharges 
 Soreness and dryness 
 Strong smelling or frothy discharge  
 Dark coloured discharge 
 Rashes or sore spots in the genitals.  
TRICHOMONIASIS 
i) One of the most commonly occurring. 
ii) Itching in Vulva 
iii) Disease almost entirely in child bearing era. 
iv) By inadequate hygiene and by sexually transmissible. 
v) By use of an infected persons towels or clothes. 
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CAUSATIVE ORGANISM:    Trichomonas  vaginalis, a Protozoan 
 
SYMPTOMS: 
i) Vaginal discharge in profuse thin creamy or slightly green. 
ii) Irritant and frothy. 
iii) Pruritis and  inflammation of the vulvae.  
iv) Dysuria, frequency of urination and low-grade urethritis. 
v) Low back or abdominal pain.  
 
 
PREVENTION  is always better than cure. 
i. Wash genitals everyday. 
ii. Wear clean underwear everyday. 
iii. Always wash genitals from front to back. 
Strictly avoid: 
1.Sprays, deodorants, and strong perfumed soap and bath products. 
2.Stress and strain since it may affect the hormonal level and may increase secretions. 
3.Sharing towels and underwear. 
4.Synthetic or nylon underwear which cause dampness of genital organs. Always wear cotton 
underwear to avoid moisture. 
5.Sexual intercourse during heavy discharges. 
6.Sexual intercourse without condoms while under treatment. 
7.Do not stop treatment when symptoms disappear –the full course of treatment is very 
important. Abstain from sexual intercourse during  treatment in order to avoid irritation of 
tissues, which are in the process of healing. 
 
Always Take 
1.Nutritious diet, to improve general health. 
2.Plenty of  water and juices to avoid urinary tract infection and its spread to the vagina or 
cervix. 
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CLINICAL STUDY 
 
Selection of patients: 
                 For this dissertation  study, 30 patients were treated in National Institute of Siddha, 
out patient department with the trial drug. 
 
Selection criteria 
Inclution criteria: 
  1. Age group 15-45  yrs 
  2. Willing to attend the OPD once in 6 days for 4 weeks 
Exclusion criteria: 
            1. Other vaginal infections 
            2. Blood stained discharge 
            3. Malignancy 
            4.  Pregnancy 
            5. Diabetis 
     Withdrawl criteria: 
1. Severe abdominal pain 
2. Any other acute illness   
Line of treatment 
             The drug Palagarai Parpam was administred internallyin dose of 130mg,  2 times a 
day with butter after food. 
Diet restriction 
 Patients were advised to avoid: 
1. Sesban 
2. Tamarind 
3. Bringal 
4. Bitter guard 
5. Spicy foods 
And were advised to take coolant foods 
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RESULTS AND OBSERVATION 
 
Results of  Bio-chemical analysis of Palagarai Parpam: 
 
Table 12. Standardisation parameters 
SL. NO Parameter Results 
1. Loss of drying @ 105 º C (%) 0.85 
2. Ash value  @ 550 º C  (%) 88.10 
3. Water Soluble , (%) 2.13 
4. Alkalinity as CaCO 3 in water  soluble  Ash, (%) 1.40 
5. Acid Insoluble  Ash , (%) 0.34 
6. p H  at 10% aqueous  solution 9.54 
 
Table 13. Qualitative Analysis 
 
SL. No Parameters Results 
1 Calcium Present 
2 Chloride Present 
3 Carbonate Present 
4 Zinc Present 
5 Magnesium Present 
 
RESULTS OF PHARMACOLOGICAL STUDIES 
 
ACUTE TOXICITY-RESULTS OF PALAGARAI PARPAM 
 
 No death was recorded during the treatment period in treated groups given upto the 
maximum of 4g/kg of Palagarai Parpam orally. The animals did not show any major 
changes in general behavior or other physiological activities. There were no significant 
differences in treated groups in the toxic symptoms. But the symptoms like continuous 
grooming, not responding to stimuli, moderate analgesia in all the group was generally 
observed in the animals (Table-14). No pathological alterations were grossly detected in vital 
organs after sacrificing. The organs of both control and treated groups were unremarkable 
and comparable to each sex. No further evidence of histopathological changes was seen.  
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Table-14. Incremental dose finding experiment and its Signs of Toxicity 
 
No Treatment Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. I 5 + - - - - - - - - - - - - - - - - - - - 
2 II 10 + - - - - + - - - - - - - - - - - - - - 
3 III 50 + - - - - + - - - - - - - - - - - - - - 
4 IV 100 + - - - - + - - - - - + - - - - - - - - 
5 V 250 + - - + + + - + - - + + - - - - - - - - 
6 VI 500 + - - + - + - + - - + + - + - - - - - - 
7 VII 1000 + - - + - + - + - -- + + - + - - - - - - 
8 VIII 2000 + - - + - + - - - - + + + + - - - - - - 
9 IX 4000 + + + + + + + + - - + + + + - - - - - - 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Increased Motor Activity 8. Tremors 9. Convulsions 10. Muscle 
Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 
15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. 
Number of Deaths (Mortality) 
 
ANTI-MICROBIAL ACTIVITY RESULTS 
The results of the antimicrobial activity indicate that the Palagarai Parpam is 
effective against standard strains of Staphylococcus aureus, Klebsiella pneumoniae, 
Trichomonas, Proteus vulgaris. The minimum inhibitory concentrations (MICs) of the 
Palagarai Parpam against the test organisms are shown in Table 15. The Palagarai Parpam 
showed activity against Staphylococcus aureus was found to be excellent. But the activity 
against Trychomonas and proteus was moderate and effective at higher dose level (Table-
15).  The control did not produce any inhibitory activity against the organisms. The zone of 
inhibition produced by Palagarai Parpam against standard strains of Candida, Esherichia 
coli, was much lower or negligible (3mm).3 
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Table15:  In vitro antimicrobial activity of 10, 20, 30µg /ml of the Palagarai Parpam. 
Organisms Mean diameter of zone of inhibition in mm 
Control 10µg/ml 20µg/ml 30µg/ml 
Esherichia coli  0 0 0 0 
Klebsiella pneumoniae 0 0 0 6 
Trichomonas vaginalis 0 0 0 6 
Staphylococcus aureus 0 6 8 13 
Proteus 0 0 6 6 
Candida albicans  0 0 0 0 
0
2
4
6
8
10
12
14
Esherichia coli Klebsiella pneumonia Trychomonas Staphylococcus
aureus
Proteus Candida albicans 
ANTIMICROBIAL ACTIVITY
Control 10µg/ml 20µg/ml 30µg/ml
 
 
CLINICAL ASSESSMENT 
 
Table 16. Age Distribution: 
 
Age Cases No. Percentage 
21-30 11 36.7 
31-40 14 46.7 
41-50 5 16.5 
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AGE DISTRIBUTION
36.7
46.7
16.5
21-30 31-40 41-50
 
 
 
According to age distribution :- 
36.7 % of cases were in below 30. 
46.7 % of cases were in below 40. 
16.5 % of cases were in below 50 
 
Table 17. Distribution of clinical symptoms of vellai noi                                                               
before and after treatment 
S. No Signs & Symptoms Before 
Treatment 
After 
Treatment 
Improvement 
1 Yellowish purulent 
discharge  
30 2 93% 
2 Pruritis vulva 17 2 88% 
3 Dysuria 15 3 80% 
4 Lower abd. pain  20 2 90% 
5 Low back pain  22 2 90.9% 
6 Odour 18 2 88.9 % 
7 Inflammation of vulva 10 0 100 % 
8 Tenderness  10 0 100 % 
9. Trichomoniasis 30 2 93.33% 
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30
2
17
2
15
1
20
2
22
1
18
2
10
0
10
0
30
2
0
5
10
15
20
25
30
White
discharge 
Prurit is vulva Dysuria Lower abd.
pain 
Low back pain Odour Inf lammat ion of
vulva
Tenderness Vaginal smear
CLINICAL SYMPTOMS OF VELLAI NOI BEFORE AND AFTER TREATMENT 
Before Treatment After Treatment
 
 
OBSERVATION  
 Yellowish purulent discharge   
 Out of 30 cases with initial symptom of white discharge only 2 cases had white 
discharge after treatment i.e  93% of cases did not have the symptom of Yellowish purulent  
discharge. 
 
Pruritus vulva 
 Out of 17 cases with initial symptom of Pruritus vulva  only 2 cases had Pruritus 
vulva after treatment i.e  88 % of cases did not have the symptom of Pruritus vulva. 
Dysuria  
 Out of 15 cases with initial symptom of Dysuria   only 3 cases had Dysuria  after 
treatment i.e  80 % of cases did not have the symptom of Dysuria. 
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Lower abdominal Pain  
 Out of 20 cases with initial symptom of Lower abdominal pain    only 2 cases  had 
Lower abdominal pain   after treatment i.e  90 % of cases did not have the symptom of Lower 
abdominal pain. 
Low back Pain  
Out of 22  cases with initial symptom of Low back  pain    only 2 cases had Low  
back pain   after treatment i.e  90.9 % of cases did not have the symptom of Low  back pain. 
Odour  
Out of 18  cases with initial symptom of  Odour only 2 cases  had  Odour  after 
treatment i.e  88.9  % of cases did not have the symptom of Odour. 
Inflammation  of   vulva 
 Out of 10  cases with initial symptom of   Inflammation of vulva,   no  cases  
had   Inflammation  of vulva   after treatment i.e  100 % of cases did not have the symptom 
of  Inflammation of vulva. 
Out of 10  cases with initial symptom of    Tenderness ,  no  cases  had   Tenderness   
after treatment i.e  100 % of cases did not have the symptom of   Tenderness. 
 
Trichomoniasis  
 Out of 30   cases with initial symptom of    Trichomoniasis only  2   cases  had   
Trichomoniasis   after treatment i.e  93.33 % of cases did not have the symptom of   
Trichomoniasis . 
From the clinical and statistical analysis, it is proved that the drug Palagarai parpam is 
stastically significant. 
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CASE SHEET OF VELLAI NOI  PATIENTS 
 
S.NO 
 
OP.NO 
 
NAME 
 
A/S 
Yel . pru 
discharge 
Pruritis 
Vulva 
Dysuria Low.abd. 
pain 
Low.back 
pain 
Odour Inf.of . 
vulva 
Tender 
ness 
Vag.smear 
Tri.vaginalis 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1. AG469 Ammu 23/F + + + + + - + - + - + + - - - - + ve - ve 
2. AG915 Girija 33/F + - - - - - + - + - + - - - - - + ve - ve 
3. AG914 Buvanerwari 26/F + - + - - + - - - - + + - - - - + ve - ve 
4. AG2239 Gunasundari 24/F + - - - - - - - + - - - - - - - + ve - ve 
5. AG2256 Sasi 32/F + + + + + + + - + - + - + - + - + ve - ve 
6. AG2358 Chellamal 31/F + - + - - + + - + - + - + - + - + ve - ve 
7. AG2377 Kanniyammal 25/F + - + - + - - - + - + - + - + - + ve - ve 
8. AG2478 Radha 42/F + - - - - - - - + - + - - - - - + ve + ve 
9. AG2035 Santhi 40/F + - + - + - + - + - - - - - - - + ve + ve 
10. AG3495 Pavithra 25/F + - + - + + + - + + + - - - - - + ve - ve 
11. AG2742 Jamela 35/F + - - - + - + - + - + - + - + - + ve - ve 
12 AG 2916 Rajeswari 40/F + - + - - - + - + - - - - - - - + ve - ve 
13 AG3170 Amithabanu 30/F + - + - + - + - + - + - + - + - + ve - ve 
14. AG3189 Amaravathi 32/F + - + - - - + - + - + - + - +  + ve - ve 
15 AG3201 Viji 22/F + - + - + - + - + - - - - - - - + ve - ve 
16 AG3245 Kumareswari 25/F + - - - - - + - + - - - - - - - + ve - ve 
17 AG3782 Kalaiyarashi 35/F + - + - - - + - + + - - - - + - + ve - ve 
18 AG3919 Reeta 25/F + - + - - - + - + - + - - - + - + ve - ve 
19 AG4421 Kalaivani 24/F + - - - + - - - + - + - - - + - + ve - ve 
20 AG4439 kaliammal 44/F + - + - - - + + + - + - - - + - + ve - ve 
21 AG4972 Kamatchi 28/F + - - - + - + + + - + - + - - - + ve - ve 
22. AG6284 Gracy 32/F + - - - - - - - - - - - - - - - + ve - ve 
23. AG6285 Susila 30/F + - + - - - + - + - + - + - - - + ve - ve 
24 AG5698 Vahitha 42/F + - - - + - + - + - + - + - - - + ve - ve 
25. AG6610 Malliga 32/F + - - - + - + - + - + - + - - - + ve - ve 
26. AG6611 Mary kalpana 39/F + - + - - - + - - - - - - - - - + ve - ve 
27 AG2567 Malar 30/F + - + - + - - - - - - - - - - - + ve - ve 
28 AG2995 Faritha 42/F + - - - + - - - - - - - - - - - + ve - ve 
29 AG2140 Kamala 39/F + - - - + - - - - - - - - - - - + ve - ve 
30 AG5316 Vithubala 32/F + - - - - - - - - - - - - - - - + ve - ve 
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BLOOD ANALYSES OF VELLAI NOI PATIENTS 
SN
O OP NO NAME A/S 
BEFORE TREATMENT AFTER TREATMENT Vaginal PH 
TC 
cells/ 
cumm 
DC ESR 
½ /1 hr 
Hb 
gm
% 
TC 
cells/ 
cumm 
DC ESR 
½ /1 hr 
Hb 
gm
% 
BT AT P
% 
L
% 
E
% 
M 
% P% 
L
% 
E
%
M
%
1. AG469 Ammu 23/F 6800 55 41 4 0 12.22 12.9 8000 54 42 4 0 4/8 12.9 6 5 
2. AG915 Girija 33/F 6000 55 42 4 0 12/22 12 6000 55 42 4 0 10/20 12 7 5 
3. AG914 Buvanerwari 26/F 8900 57 38 4 0 6/14 12.1 9000 57 38 4 0 6/10 12.5 6 4.5 
4. AG2239 Gunasundari 24/F 6900 54 40 5 1 5/13 12.4 7000 54 40 5 1 5/10 12 6 5 
5. AG2256 Sasi 32/F 7300 55 38 7 0 10/22 12.6 6200 50 43 5 0 7/16 15 7 4.5 
6. AG2358 Chellamal 31/F 7000 55 40 5 0 10/22 12 7000 55 38 5 0 10/20 14 6.5 5 
7. AG2377 Kanniyammal 25/F 6800 52 40 7 1 10/22 12 7000 50 40 5 1 10/20 12 6 5 
8. AG2478 Radha 42/F 10800 56 40 4 0 10/22 14 10800 50 40 4 0 10/20 14 5.5 5 
9. AG2035 Santhi 40/F 6800 60 35 4 0 8/19 12 7000 60 40 4 0 7/14 12 6 4 
10. AG3495 Pavithra 25/F 7000 54 40 4 0 6/12 10 7000 50 40 4 0 6/12 10 6 4 
11. AG2742 Jamela 35/F 6200 51 40 7 0 7/15 12 7000 50 40 6 0 6/12 12 6.5 4 
12 AG 2916 Rajeswari 40/F 6500 60 35 5 0 2/5 13 6000 55 35 4 0 2/4 12 7 5 
13 AG3170 Amithabanu 30/F 7300 60 36 3 0 6/13 12 7000 55 35 3 0 6/12 12 6 5.5 
14. AG3189 Amaravathi 32/F 6300 52 44 3 0 6/12 5 7200 53 42 2 0 9/20 16 7 5 
15 AG3201 Viji 22/F 9100 53 40 5 0 6/13 10 9100 50 40 4 0 6/12 10 6 4.5 
16 AG3245 Kumareswari 25/F 7300 52 40 4 0 10/20 12 7200 50 40 4 0 10/20 12.5 6 5 
17 AG3782 Kalaiyarashi 35/F 7400 56 40 4 0 8/16 12 7400 50 40 4 0 8/10 11 7 5 
18 AG3919 Reeta 25/F 7000 50 42 6 0 3/7 15 7000 50 40 4 0 3/7 14 6 5 
19 AG4421 Kalaivani 24/F 6800 50 40 4 1 6/15 10 7000 55 40 4 1 3/6 11 6 5.5 
20 AG4439 kaliammal 44/F 7000 52 46 2 1 5/12 15 7000 50 40 2 1 5/10 15 5.5 4 
21 AG4972 Kamatchi 28/F 6500 57 40 3 0 6/10 10 6500 50 40 2 0 6/10 10 6 4 
22. AG6284 Gracy 32/F 6800 56 40 4 0 11/22 10 6000 56 40 4 0 10/20 11 5.5 4 
23. AG6285 Susila 30/F 5000 50 49 1 1 5/10 11 5000 50 40 2 1 5/10 11 6 5 
24 AG5698 Vahitha 42/F 6800 50 40 4 0 6/12 12 7000 50 35 4 0 5/10 13 7 4 
25. AG6610 Malliga 32/F 6200 59 38 3 0 20/40 10 6200 50 38 4 0 10/20 12 6 4 
26. AG6611 Mary kalpana 39/F 7200 54 42 3 0 4/8 10 7200 50 42 3 0 4/8 10 6.5 4.5 
27 AG2567 Malar 30/F 5000 55 43 2 0 6/15 11.2 5500 55 40 2 0 6/12 11.2 6 4 
28 AG2995 Faritha 42/F 6200 50 41 2 0 5/12 12.6 6000 50 45 2 0 6/12 13 6.5 5 
29 AG2140 Kamala 39/F 7900 54 42 4 0 8/16 12.3 7000 55 40 5 0 2/4 12 7 5 
30 AG5316 Vithubala 32/F 7000 54 40 4 0 2/4 12 7000 50 35 4 0 2/4 12 5.5 4 
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BLOOD ANALYSIS OF  VELLAI  NOI  PATIENTS 
SNO OPNO NAME A/S 
BEFORE TREATMENT AFTER TREATMENT VDRL 
TRBC/ 
million 
RBS 
mg%
Urea 
mg%
Creatinine
mg% 
Choles
terol 
mg% 
TRBC/ 
million
RBS 
mg%
Urea 
mg%
Creatinine
mg% 
Choles
terol 
mg% 
BT AT
1. AG469 Ammu 23/F 4.3 98 18 0.6 150 4 95 18 0.6 130 -ve -ve 
2. AG915 Girija 33/F 4.2 95 15 0.6 140 4.2 90 15 0.6 140 -ve -ve 
3. AG914 Buvanerwari 26/F 4 78 24 0.8 148 4 78 24 0.8 148 -ve -ve 
4. AG2239 Gunasundari 24/F 4.2 73 21 0.8 140 4 72 20 0.8 140 -ve -ve 
5. AG2256 Sasi 32/F 3.5 112 21 0.8 120 4.3 122 28 0.8 130 -ve -ve 
6. AG2358 Chellamal 31/F 3 110 20 0.8 130 3.5 110 20 0.8 120 -ve -ve 
7. AG2377 Kanniyammal 25/F 3 81 19 0.8 120 3 80 18 0.8 120 -ve -ve 
8. AG2478 Radha 42/F 4.4 74 19 0.7 130 4.4 70 19 0.7 120 -ve -ve 
9. AG2035 Santhi 40/F 4.3 89 25 0.8 140 4.2 70 20 0.8 120 -ve -ve 
10. AG3495 Pavithra 25/F 4 80 20 0.7 120 4 80 20 0.6 130 -ve -ve 
11. AG2742 Jamela 35/F 3.6 86 28 0.8 207 4 86 20 0.8 180 -ve -ve 
12 AG 2916 Rajeswari 40/F 4 76 19 0.6 163 4 70 18 0.6 160 -ve -ve 
13 AG3170 Amithabanu 30/F 4 120 31 0.8 193 4 120 30 0.8 180 -ve -ve 
14. AG3189 Amaravathi 32/F 4.2 84 21 0.8 200 4.5 99 14 0.7 200 -ve -ve 
15 AG3201 Viji 22/F 4.8 124 21 0.8 173 4.4 120 20 0.8 170 -ve -ve 
16 AG3245 Kumareswari 25/F 4 120 18 0.8 120 4 120 16 0.8 125 -ve -ve 
17 AG3782 Kalaiyarashi 35/F 3.5 125 18 0.6 160 4 120 16 0.6 155 -ve -ve 
18 AG3919 Reeta 25/F 4.4 120 19 0.8 178 4 120 18 0.8 170 -ve -ve 
19 AG4421 Kalaivani 24/F 4.2 180 15 0.6 190 4 150 15 0.6 185 -ve -ve 
20 AG4439 kaliammal 44/F 4 75 27 0.8 230 4 70 20 0.8 200 -ve -ve 
21 AG4972 Kamatchi 28/F 4 80 20 0.8 190 4 80 18 0.8 180 -ve -ve 
22. AG6284 Gracy 32/F 4 99 22 0.8 121 4 90 20 0.8 120 -ve -ve 
23. AG6285 Susila 30/F 2.5 100 18/ 0.6 118 3 90 18 0.6 120 -ve -ve 
24 AG5698 Vahitha 42/F 4 125 17 0.6 125 4 120 16 0.6 120 -ve -ve 
25. AG6610 Malliga 32/F 2.1 80 13 0.8 128 3 80 13 0.8 120 -ve -ve 
26. AG6611 Mary kalpana 39/F 3.5 85 12 0.8 102 3 85 12 0.6 120 -ve -ve 
27 AG2567 Malar 30/F 3.5 83 14 0.8 169 3.5 80 14 0.8 160 -ve -ve 
28 AG2995 Faritha 42/F 4.2 87 15 0.8 228 4.2 85 15 0.8 220 -ve -ve 
29 AG2140 Kamala 39/F 4 84 14 0.4 197 4 83 14 0.5 187 -ve -ve 
30 AG5316 Vithubala 32/F 4 80 12 0.8 190 4 80 12 0.7 180 -ve -ve 
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URINE ANALYSIS OF  VELLAI  NOI  PATIENTS 
SNO OP/IPNO NAME A/S 
BEFORE TREATMENT AFTER TREATMENT 
Alb Sug 
Deposits 
Alb Sug 
Deposits 
Pus 
cells 
Epi 
cells RBC’s 
Casts/ 
crystals 
Pus 
cells 
Epi 
cells RBC’s 
Casts/ 
crystals 
1. AG469 Ammu 23/F Nil Nil 2-3 2-3 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
2. AG915 Girija 33/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-6 Nil Nil 
3. AG914 Buvanerwari 26/F Nil Nil 4-6 2-4 Nil Nil Nil Nil 2-4 5-6 Nil Nil 
4. AG2239 Gunasundari 24/F Nil Nil 2-4 4-6 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
5. AG2256 Sasi 32/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
6. AG2358 Chellamal 31/F Nil Nil 4-6 2-4 Nil Nil Nil Nil 4-6 2-4 Nil Nil 
7. AG2377 Kanniyammal 25/F Nil Nil 2-3 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
8. AG2478 Radha 42/F Nil Nil 1-2 1-2 Nil Nil Nil Nil 2-4 2-5 Nil Nil 
9. AG2035 Santhi 40/F Nil Nil 4-6 2-4 Nil Nil Nil Nil 1-2 4-5 Nil Nil 
10. AG3495 Pavithra 25/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
11. AG2742 Jamela 35/F Nil Nil 2-4 2-4 Nil Nil Nil Nil 1-2 2-3 Nil Nil 
12 AG 2916 Rajeswari 40/F Nil Nil 2-4 1-2 Nil Nil Nil Nil 1-2 1-2 Nil Nil 
13 AG3170 Amithabanu 30/F Nil Nil 1-2 2-5 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
14. AG3189 Amaravathi 32/F Nil Nil 1-2 2-6 Nil Nil Nil Nil 2-5 4-6 Nil Nil 
15 AG3201 Viji 22/F Nil Nil 1-2 2-3 Nil Nil Nil Nil 3-5 2-5 Nil Nil 
16 AG3245 Kumareswari 25/F Nil Nil 1-2 1-2 Nil Nil Nil Nil 4-5 1-4 Nil Nil 
17 AG3782 Kalaiyarashi 35/F Nil Nil 1-2 2-3 Nil Nil Nil Nil 2-4 1-2 Nil Nil 
18 AG3919 Reeta 25/F Nil Nil 1-2 2-3 Nil Nil Nil Nil 2-4 1-2 Nil Nil 
19 AG4421 Kalaivani 24/F Nil Nil 1-2 2-3 Nil Nil Nil Nil 2-4 1-2 Nil Nil 
20 AG4439 Kaliammal 44/F Nil Nil 1-2 2-3 Nil Nil Nil Nil 2-4 1-2 Nil Nil 
21 AG4972 Kamatchi 28/F Nil Nil 1-2 1-2 Nil Nil Nil Nil 1-2 1-2 Nil Nil 
22. AG6284 Gracy 32/F Nil Nil 1-2 4-6 Nil Nil Nil Nil 2-3 2-5 Nil Nil 
23. AG6285 Susila 30/F Nil Nil 1-2 2-3 Nil Nil Nil Nil 2-4 2-3 Nil Nil 
24 AG5698 Vahitha 42/F Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
25. AG6610 Malliga 32/F Nil Nil 1-2 2-4 Nil Nil Nil Nil 2-4 2-4 Nil Nil 
26. AG6611 Mary kalpana 39/F Nil Nil 2-4 1-2 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
27 AG2567 Malar 30/F Nil Nil 3-4 1-6 Nil Nil Nil Nil 1-2 1-2 Nil Nil 
28 AG2995 Faritha 42/F Nil Nil 1-2 2-4 Nil Nil Nil Nil 1-2 2-6 Nil Nil 
29 AG2140 Kamala 39/F Nil Nil 2-3 2-4 Nil Nil Nil Nil 1-2 1-3 Nil Nil 
30 AG5316 Vithubala 32/F Nil Nil 1-2 1-2 Nil Nil Nil Nil 1-2 2-4 Nil Nil 
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DISCUSSION 
 
 The drug palagari parpam was selected  to find its efficacy in the treatment of vellai 
noi. The literary evidence strongly support anti-inflammatory and analgesic activity of the 
drug.  
  
 Bio-chemical analysis of the drug palagari parpam reveals, the presence of calcium, 
chloride, carbonate, zinc and magnesium. 
  
 Zinc kills the gram +ve and gram –ve bacterium, fungi, yeast and candida.  
  
 Magnesium and zinc (metalic oxides) effective against gram +ve bacterium and 
candida.  
  
Anti-microbial activity of the drug was done in Vel’s College, Pallavaram. The drug 
Palagari parpam has  anti-microbial activity  against  Staphylococcus aureus, Klelbsiella  
Pneumoniae, Trychomonas, and Proteus vulgaris,  
 
             In acute toxicity study, oral administration of Palagarai parpam did not produce any 
mortality in mice upto a dose level of 4 gm/kg. This may be due to the broad non- toxic range 
of the drug. 
   
              The active principles of the Palagarai Parpam elicited antibacterial activity 
appeared to have remarkable activity against few bacteria. This observation could possibly 
justify the usefulness of the Palagarai Parpam as clinical reports in siddha system of 
medicine. The Palagarai Parpam presents narrow spectrum antibacterial activity.  
                  
There was no activity against E. coli and Candida. However, the activity shown 
against susceptible organisms, as observed in this study, would appear to justify the 
ethnomedicinal use in recipes for infections. Further studies required characterizing and 
identifying the bioactive constituent responsible for the specific antimicrobial activity. 
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SIDDHA ASPECT 
According to Theraiyar dearrangement of Pitha causes Meganoigal. 
 “gfHgpj;j tpe;ijayhJ Nkfk; tuhJ” 
According to arusuvai theory, 
 “gpj;j kjpfhpg;gpd; NgRk; ghpfhuk; 
 Rj;jj; JtNuhL nrhy;ypdpg;Gr; - rj;jhFk; 
 ifg;Gr; RitNa fUjtjd; tPW 
 va;g;gilA nkd;W iuj;jhhpq;F” 
 Kaippu suvai reduces the pitha kutram.  The drug Palagarai has kaipu suvai.  So it 
neutralizes the pittha kutram. 
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SUMMARY AND CONCLUSION 
  
 The drug Palagarai parpam has selected  for the study to evaluate its efficacy in 
management of Vellai noi 
               The literature collection describes the Anti- microbial activity of the drug  
 
               The chemical analysis of the drug Palagarai parpam reveals the presence of 
calcium, chloride, carbonate, zinc and magnesium 
 
              Pharmacological studies showed that the drug has significant Anti- microbial 
activity at the dose of 400 mg/kg and no significant adverse effects 
 
              Anti- microbial study reveal that the drug  Palagarai parpam has anti- microbial 
effect against  Staphylococcus aureus, Klebsiella pneumoniae, Trychomonas vaginalis & 
Proteus vulgaris. 
             30 patients with signs and symptoms of Vellai Noi were selected, and a thorough 
observation was made.  
            Clinically, no adverse effects were reported during the course of treatment 
The improvement shown after treatment in terms of clinical symptoms viz. Yellow purulent 
discharge, Pruritis vulva, Dysuria, Lower abdominal pain, Low back pain, Odour, 
Inflammation of vulva& Tenderness were statistically significant. 
Conclusion 
 From the pharmacological studies and clinical study, it was concluded that the drug 
Palagarai parpam  has significant anti- microbial activity . Thus it gives us a new hope in the 
management of Vellai Noi (Leucorrhoea). 
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 X-Rays of Calcaneal Spur 
 
 
 
 
 
 
 
 
 
 
 
Figure No.1. Photomicrograph of rat Femur in Group I (Normal control) 
 
 
 
Figure No.2.  Photomicrograph of rat Femur in Group II, treated with Korai 
kizhangu  choornam @ 200 mg/kg showing normal bone 
 
Figure No.3. Photomicrograph of rat Femur in Group III, treated with Korai 
kizhangu choornam @   400 mg/kg showing normal bone 
 
From 
        Dr. P. Kavitha, 
        M.D.(S) 2rd  year, 
        Dept. of Gunapadam 
        National Institute of siddha, 
        Chennai-47. 
TO 
      The head of the department, 
       Dept. of Gunapadam 
       National Institute of siddha, 
       Chennai-47 
Respected sir, 
  Sub: regarding- topic selection 
               I am doing my 2rd M.D(S) in this institute. Here , I have selected the following 
topics as my dissertion work (2005-2008). 
 
Topic-1:  study on Palagarai parpam for vellai noi 
 
Intended therapeutic dose: 1-1.5 kundrimani(130-195mg)for 2 times a day. 
 
Vehicle: Butter(vennai) 
 
Days: ½ mandalam(24 days) 
 
Reference: Padhatha guna vilakam(Thathu Jeeva Vaguppu),pageno:261 
 
 
Topic 2: study on  Korai kizhangu choornam for Kuthi kaal vatham 
 
Intended therapeutic dose:   1 gm for 3 times a day. 
 
Vehicle: water 
 
 Days: 1 mandalam(48 days) 
 
 Reference: Gunapadam Mooligai Vaguppu: page no:410 
 
         So please kindly permit me and forward this topic for me to proceed my dissertion 
work. 
    Thanking you 
          Yours faithfully, 
Date : 24.05.2007)          
         (P. Kavitha)   
Place: Chennai- 47. 
 
     PROTOCOL 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG                                 
KORAI KIZHANGU CHOORNAM  FOR THE TREATMENT OF         
KUTHI KAAL VATHAM ( CALCANEAL SPUR ) 
                                                                                        - A PILOT STUDY  
BY 
 
         Dr. P. KAVITHA, PG STUDENT , DEPT. OF GUNAPADAM, NIS, CHENNAI. 
 
1. BACKGROUND          
               A calcaneal spur is a small bony projection that is formed on the calcaneas 
or heel bone. It is caused by putting too much pressure on the sinew on the soles of 
the feet, usually over a period of long time. 
           In Gunapadam Mooligai by K.S. Murugesha Mudhaliyar, Korai Kizhangu 
was mentioned for Kuthi Kaal Vatham, whose efficacy has to be evaluated.  
 
2. ABOUT THE DRUG 
   a. Trial drug, dosage and duration  
 Korai Kizhangu Choornam – 1 g b.d.  with honey after food for 48 days 
   
       “ «¾¢º¡Ãõ À¢ò¾õ «ÉüÈ¡¸õ ³Âí 
    Ì¾¢Å¡¾õ §º¡Àõ ¦¸¡ÊÂ Ó¾¢÷Å¡ó¾¢ 
    Â¡¨Ãò¦¾¡¼÷ó¾¡Öõ «ùÅÅ÷ì¦¸ Ä¡íÌÇòÐì 
    §¸¡¨Ãì¸¢Æí¨¸ì ¦¸¡Î “  
 
   As Korai Kizhangu is mentioned in the above text for Kuthi Vatham, the drug Korai 
Kizhangu is selected for Kuthi Kaal Vatham.   
 
 b. Diet 
  Avoid tomato, cabbage, cauli flower, potato, green plantain, tamarind, brinjal, bitter 
guard and sesban,  
 
c. Mukkutra Vaerupadu 
 As it is mentioned as “Å¡¾ÁÄ¡Ð §ÁÉ¢ ¦¸¼¡Ð ”  
     in Theran karisal, naadi for Kuthi Kaal Vatham is Vatham. So it is came to know that 
the siddha aetiology for Kuthi Kaal Vatham is Vatha and due to variation of vatha 
kuttram. 
   “Å¡¾¦ÁÛõ ¿¡ÊÂÐ §¾¡ýÈ¢ø º£¾õ 
   ------------------------------------------- 
   ------------------------------------------- 
   º£¾ÓÚõ ¸¢Ã¡½¢ Á§¸¡¾Ãõ ¿£Ã¡¨Á 
   ¾¢ÃûÅ¡Ô Ý¨Ä ÅÄ¢ ¸ÎôÒ ¾£¨Ã”     
 
3. AIMS  
Primary aim 
Font: TSCu_InaiMathi
 To estimate the efficacy of Korai  Kizhangu Choornam in the treatment of Kuthi 
Kaal Vatham. 
 
Secondary aim 
      To find out the side effects of the drug, if any. 
 
4. POPULATION AND SAMPLE  
 The population consists of Kuthi Kaal Vatham patients (Spike of Bone at the 
anterior edge of the Calcaneal tuberosity) satisfying the inclusion and exclusion criteria 
mentioned below. 
 
 The sample consists of Kuthi Kaal Vatham patients attending the OPD of 
Ayothidoss Pandidhar Hospital of the National Institute of Siddha, Chennai – 47. 
 
 
5. SAMPLE SIZE 
              The trial size will be 30 patients aged between 30 – 45 years. 
 
 
6. SELECTION CRITERIA              
    a.  Inclusion criteria 
1. Age group 30 – 45 years, 
  2.   Willing to attend the OPD once in a weak for 7 weeks. 
  3.   Heel Pain. 
  4.   X-Ray heel shows calcaneal growth. 
       
    b. Exclusion criteria                                                                                                          
  1. Rheumatoid arthritis,  
  2. Gout, 
  3. Osteoarthritis, 
  4. Osteomalacia, 
  5. Osteosporosis, 
  6. Osteosarcoma. 
 
    c.  Withdrawal criteria 
   1.  Drug intolerance. 
   2.  Any other acute illness. 
   
 
7. TESTS & ASSESSMENTS 
a. Clinical assessment 
1 .Pain over ball of heel. 
                  2. Tenderness on plantar aspect of heel. 
            3.  Swelling at the attachment of Plantar fascia. 
b. Tests 
 
   Blood 
TC (Cells / Cu mm), DC (%), ESR (mm / hr), Hb (g %), Sugar (mg %), 
Serum calcium level. 
    Urine 
  Albumin, Sugar, Deposit 
   X ray foot   
 
      c. Siddha assessment 
          En vagai thaervu, 
          Neer kuri, 
          Nei kuri. 
 
8. CONDUCT  
 
 Kuthi Kaal vatham patients satisfying the inclusion and exclusion criteria are 
selected for the study(Form 1). Informed consent will be obtained from the patients. 
 The trail patients will be issued drugs for 7 days at a time. They will be instructed 
to come for next clinic visit after 7 days. Also, they will be asked to bring back the 
unconsumed drug during their next visit and return the same. Clinical assessments will be 
done during each clinic visit. Lab tests and X-ray will be carried out before admission to 
the trial. 
 
9. FORMS  
 
    Form 1  
 Selection proforma used before admission to the trial. 
 
    Form 2  
 Assessment proforma used during clinic visits once in 7 days. 
 
10. ANALYSIS 
              The difference in the proportions of patients with signs& symptoms before and 
after treatment will be analysed using paired X2– tests. 
 
PROTOCOL 
 
PRE-CLINICAL PHARMACOLOGICAL EVALUATION OF KORAI KIZHANGU 
CHOORNAM  FOR ANTI-INFLAMMATORY AND ANALGESIC  ACTIVITY 
 
                                                         BY 
 
          Dr. P. KAVITHA, PG STUDENT , DEPT. OF GUNAPADAM, NIS, CHENNAI. 
 
 
 
1. BACKGROUND 
 
 The drug Korai kizhangu choornam has been mentioned in Gunapadam Mooligai 
for Nalir suram, Muppini, kurithi azhai noi, Sura vagaigal, Neer vaetkai, kazhichal, 
Payithia thodam, pitttha thagam, Kaba rogam, Kuthi kaal vatham, Vandhi. It is believed 
that this drug will have good effect against Kuthi kaal vatham. So this drug has been 
selected for the evaluation of anti inflammatory and analgesic activity in Kuthi Kaal 
Vatham. 
 
2. AIMS 
 
 Primary aim 
 
  To assess the anti-inflammatory and analgesic activity of Korai Kizhangu 
Choornam in albino rats and analgesic activity in swiss albino mice 
 
 Secondary aim 
 
  1. Biochemical analysis, 
  2. Physical properties, 
  3. Pharmacognostic study, 
                        4. Phytochemical study. 
 
3. TEST COMPOUND 
 
 Korai Kizhangu Choornam 
 
Reference:  Gunapadam  Mooligai 
 
4. INTENDED THERAPEUTIC USE 
 
 Korai Kizhangu Choornam 1 g  b.d with honey is given for for Kuthi Kaal 
Vatham 
 
5. ROUTE OF ADMINISTRATION 
 
 Oral route 
 
 
 
 
6. EXPERIMENTAL DETAILS 
 
A. EVALUATION OF ANTI-INFLAMMATORY ACTIVITY 
 
1. CARRAGEENAN INDUCED PAW OEDEMA 
 
Acute inflammation will be produced by subplantar injection of 0.1 ml of 1% 
suspension of carrageenan in normal saline in the right hind paw of the rats. Paw volume 
will be measured plethysmometrically at ‘0’ to ‘2’ hours after carrageenan injection. The 
animals will be divided into three groups. The animals will be treated with Korai 
Kizhangu Choornam orally. Palm jaggery treated animals will serve as control, and 
Diclofenac sodium (45mg/kg orally) will be administered as standard drug. The drugs 
will be administered simultaneously with carrageenan injection. Mean increase in paw 
volume will be measured and percentage of inhibition will be calculated. 
 
TEST GROUPS 
 
Group number Test groups No. of animals 
1 Control (Palm jaggery) 6 [3M+3F] 
2 Test dose (5mg) 6 [3M+3F] 
3 TD (10 mg) 6 [3M+3F] 
4 TD (15 mg) 6 [3M+3F] 
5 Standard drug (Diclofenac sodium 
phosphate) 
6 [3M+3F] 
 
OBSERVATIONS 
 
 Paw oedema- the paw volume will be measured just before and at ½, 1, 1½ and 2 
hours after administration of carrageenan by the volume displacement method using a 
plethismometer. 
 
2. FREUND’S COMPLETE ADJUVANT INDUCED ARTHRITIS 
 
The right hind foot will be measured for thickness with the aid of a 
micromanometer. The foot will be injected with Freund’s adjuvant; 0.05ml will be given 
intradermally beneath the plantar surface. Korai Kizhangu Choornam at varying doses 
will be administered orally to different groups of animals daily for 28 days. The thickness 
of the injected foot will be measured and the percent increase in thickness will be 
calculated. 
 
 
 
 
 
 
 
 
TEST GROUPS 
 
Group number Test groups No. of animals 
1 Control (palm jaggery) 6 [3M+3F] 
2 Test dose (5 mg) 6 [3M+3F] 
3 TD (10 mg) 6 [3M+3F] 
4 TD (15 mg) 6 [3M+3F] 
5 Standard drug (Diclofenac sodium 
phosphate) 
6 [3M+3F] 
 
 
 
 
OBSERVATIONS 
 
 Paw oedema- the paw volume will be measured just before and at ½, 1, 2, 4, 8, 12 
and 24 hours after administration of Freund’s adjuvant by using a caliper ruler. 
 
B. EVALUATION OF ANALGESIC ACTIVITY 
 
EDDY’S HOT PLATE METHOD 
 
 Analgesic activity of Korai kizhangu choornam will be assessed by the Eddy’s 
hot plate method in mice. Groups of 6 mice of either sex with an initial weight of 22 to 41 
grams will be used. The temperature will be controlled for 55° to 56°C. The animals will 
be placed on the hot plate and a stopwatch will record the time until either licking or 
jumping occurs. The latency will be recorded before and after 15, 30, 60 and 90 minutes 
following oral or intraperitoneal administration of the test or the standard compound. 
 
TEST GROUPS 
 
Group number Test groups No. of animals 
1 Control (Palm jaggery) 6 [3M+3F] 
2 Test dose (5 mg) 6 [3M+3F] 
3 TD (10 mg) 6 [3M+3F] 
4 TD (15 mg) 6 [3M+3F] 
5 Standard drug (Diclofenac 
sodium phosphate) 
6 [3M+3F] 
 
OBSERVATION 
 
 Licking of the fore or hind paws 
 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG                                 
KORAI KIZHANGU CHOORNAM  FOR THE TREATMENT OF         
KUTHI KAAL VATHAM ( CALCANEAL SPUR ) 
    
       - A PILOT STUDY 
 
    CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
 I certify that I have disclosed all details about the study in the terms readily understood               
by the patient. 
 
Date: _____________ 
                                                            Signature: ________________ 
Station: ___________ 
                                                            Name: ____________________ 
 
                                              
                                                 CONSENT BY PATIENT 
 
  I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of the drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 
  I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 
  I, exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of Korai kizhangu choornam on Kuthi Kaal Vatham. 
 
  Date: _____________                                            
                                                                Signature: _________________ 
  
 Station: _____________                        Name: _____________________ 
 
                                                                Signature of witness: _____________ 
 
 
 Date: ____________                             Name: ___________________   
   
 Station:  ___________                          Relationship: _________________ 
     
 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG KORAI 
KIZHANGU CHOORNAM FOR THE TREATMENT OF 
KUTHIKAAL VATHAM ( CALCANEAL SPUR  ) 
 
- A PILOT STUDY 
 
FORM-I   SELECTION PROFORMA 
 
 
1. O.P.No / I.P No:  ________ 2.  Bed No: ________ 3. S.No: ________    
 
4. Name: ________________ 5. Age (years):         
 
6. Occupation: ____________________  7. Income: ____________________ 
 
8. Address:  
  
 
                                                              
9. Complaints and duration:  
 
 
 
10. History of present illness:  
 
  
11. Past history:  
 
 
12. Family history:  
 
 
13. Menstrual & Obstetric history:  
 
 
    
 
 
Habits                                                                      Yes ( 1 )         No ( 2 ) 
 
14. Betalnut chewer                          
 
15. Non-vegetarian 
 
16. Alcoholic                                                               
 
17. Smoking 
 
 
 
 
GENERAL EXAMINATION 
 
 
18. Weight (kg)                                                    
        
19. Temperature (°F)        . 
  
20. Pulse rate / minute                                        
 
21. Heart rate / minute        
 
22. Respiratory rate / minute                             
   
23. Blood pressure (mmHg)                              /       / 
 
                                                      1. Yes                   2. No 
24. Pallor                                 
 
25. Jaundice                       
 
26. Cyanosis 
           
27. Lymphadenopathy 
  
28. Pedal oedema  
  
29. Clubbing                                
 
30. Jugular vein pulsation           
    
 
VITAL ORGANS EXAMINATION 
 
                                                 1. Normal            2. Affected 
31. Heart                                                                                    _________________ 
 
32. Lungs                                                                                  _________________ 
  
33. Brain                                                          ________________ 
 
34. Liver                             ________________ 
 
35. Kidney                                            ________________ 
 
36. Spleen                                   __________________ 
 
37. Stomach                                                                               __________________ 
 
38. Bones ( Calcaneal Bone )                            __________________ 
 
                         
 
 
CLINICAL EXAMINATION 
 
              SIGNS AND SYMPTOMS            
 
                              1. Yes                2. No 
   39. Tenderness 
         
40. Morning stiffness 
                                 
   41. Localized swelling of the foot 
                                                
42.Warmth 
 
43.Colour change 
        
      44. Pain during rest 
 
      45. Pain during standing 
       
      46. Pain during walking      
 
    SIDDHA SYSTEM OF EXAMINATON 
 
      IYMPORI 
                                      1. Normal        2. Affected 
  
47. Mei             _____________________ 
 
48. Vaai                    ______________________ 
 
49. Kan              _____________________ 
 
50. Mookku                        _____________________ 
 
51. Sevi                              _____________________ 
  
 
 
 
 
 
KANMENTHIRIUM  
   
  
52. Kai              _____________________ 
 
53. Kaal        _____________________ 
 
54. Vaai        _____________________ 
 
55. Eruvai        ____________________ 
 
56. Karuvaai        _____________________ 
 
PARUVA  KAALAM 
 
 
57. Kaar kaalam            58.Koothir kaalam                
  
59. Elavenil kaalam              60. Muthuvenil kaalam 
   
61. Munpani kaalam             62. Pinpani kaalam     
 
THINAI 
 
 63 Kurunji                  64. Mullai             65. Marutham     
 
66. Neithal            67. Paalai 
      
 
YAKKAI 
68. Vali                69. Azhal          70. Iyam     
  
71. Valiazhal     72. Valiaiyam          73. Azhalvali   
    
74. Azhaliyam   75. Iyavali           76. Iyaazhal  
  
 GUNAM 
 
 77. Sathuva gunam                  78. Rajo gunam         
 
 79. Thamo gunam 
      
 
 
 
 
 
 
 
UYIR THATHUKKAL 
      
 VALI     
                                        1. Normal       2. Affected 
 
80. Pranan                                                                 ____________________ 
                                                      
81. Abanan                                        _____________________ 
 
82. Samanan                                         ____________________ 
 
83. Udhanan                                        _____________________ 
 
84. Viyanan                                        _____________________ 
 
85. Nagan                                        _____________________ 
 
86. Koorman                                         ____________________ 
 
87. Kirukaran                                       _____________________ 
 
88. Devathathan                                    ______________________ 
 
89. Tananjeyan                  _____________________ 
  
    
 AZHAL 
                                         1. Normal          2. Affected 
 
90. Anala pittham            ____________________ 
 
91. Prasaka pittham             __________________ 
 
92. Ranjaka pittham                       ______________________ 
 
93. Aalosaka pittham                     ______________________ 
 
94. Saathaka pittham                 ______________________  
      
 IYAM 
                                     1. Normal          2. Affected                                     
 
95. Avalambagam          ______________________ 
 
96. Kilethagam                                                         _____________________  
 
97. Pothagam                          ______________________ 
 
 
98. Tharpagam                _______________________     
 
99. Santhigam          ______________________ 
 
        
 UDAL THATHUKKAL 
                                     
      1. Normal         2. Affected 
100. Saaram                      _______________________ 
  
101. Chenneer                                                         _______________________ 
 
102. Oon                              _____________________ 
 
103. Kozhuppu                    _______________________ 
 
104. Enbu                       _______________________ 
 
105. Moolai                                      _______________________ 
 
106. Suronitham         _______________________ 
         
 
  ENVAGAI THERVUKAL 
 
                                    1. Normal        2. Affected 
107. Naa                                          _____________________ 
 
108. Niram                                      _____________________ 
 
109. Mozhi                               _____________________ 
 
110. Vizhi                                                            ______________________   
               
    
Malam        1. Normal       2. Affected     
 
111. Niram                  ______________________ 
 
112. Thanmai                  ______________________ 
    
Moothiram    
 
Neerkuri   
 
113. Niram                         ______________________ 
114. Eadai                                       _____________________ 
                                
115. Manam                            ______________________  
 
116. Nurai                         ______________________ 
 
117. Enjal                               ______________________ 
 
 
Neikuri:  118.Vali                        119. Azhal                    120. Iyam      
 
Naadi:    121. Vali             122. Azhal                 123. Iyam         
   
     124. Valiazhal                 125. Valiiyam              126. Azhalvali   
  
     127. Azhaliyam               128. Iyavali                 129. Iyaazhal    
    
Sparisam:       130. Mithaveppam         131. Miguveppam         
                    
 132. Thatpam 
 
INVESTIGATION 
      
BLOOD 
133. TC (cells /cumm): 
 
134. DC (%):    1. P                   2. L                    3. E                      4. B                  
 
  5. M                       
 
135. Hb (gms %):                  . 
 
136. ESR (mm/hr):        1. 1/2hr                           2.1hr 
 
137. Blood Sugar (R) (mg %): 
 
138. Blood Urea (mg %): 
 
139. Blood Uric acid 
 
140. Serum Creatinine (mg %):              .  . 
  
141. Serum Cholesterol (mg %): 
 
URINE 
 
142. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +    
                                                                                                                              
143. Sugar:            0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
 
144. Deposit                           1. Yes          2. No 
 
1. Pus cells                       
 
2. Epithelial cells             
 
3.. RBC                               
 
4.. Crystals                             
  
145.  X – ray foot 
 
 
 
 
146. ADMITTED TO TRIAL:     1.Yes          2. No   
 
If yes   
 
147. S. No:    
                 
148. I.P / O.P       1. I.P        2. O.P  
 
149. Drug issued for OP patient (g): 
 
 
 
Station                    
Signature of Investigator                              
 
Date:            
Signature of Medical Officer 
 
                                                      
 
 
 
 
        
                                          
                                                        1    
AN OPEN CLINICAL TRIAL OF KORAI KIZHANGU CHOORNAM   
FOR THE TREATMENT OF KUTHI KAAL VATHAM 
- A PILOT STUDY 
 
FORM II-ASSESSMENT PERFORMA 
 
1. OP/IP No:_________________              2.BED No:_______3.S.No:_______________ 
 
4. NAME:__________________________ 
 
5. DATE OF ADMISSION: 
 
6. DATE OF ASSESSMENT: 
 
7. DAY OF ASSESSMENT: 
 
CLINICAL EXAMINATION 
 
     SIGNS AND SYMPTOMS          
                             1. Yes                2. No 
   8. Tenderness  
        
9. Morning stiffness 
                                 
  10. Localized swelling of the foot 
                                                
11. Warmth 
                                                                            
12.  Colour change 
        
      13. Pain during rest 
 
14. Pain during standing 
 
 15. Pain during walking      
  
 
  ENVAGAI THERVUKAL 
                                    1. Normal        2. Affected 
16. Naa                                          _____________________ 
 
17. Niram                                      _____________________ 
 
18. Mozhi                               _____________________ 
 
19. Vizhi                                                            ______________________   
          
Malam        1. Normal       2. Affected     
 
20. Niram                  ______________________ 
 
21. Thanmai                  ______________________ 
    
Moothiram    
         
Neerkuri   
 
22. Niram                         ______________________ 
 
23. Eadai                                       _____________________ 
                                
24. Manam                            ______________________  
 
25. Nurai                         ______________________ 
 
26. Enjal                               ______________________ 
 
 
Neikuri:  27.Vali                            28. Azhal                       29. Iyam      
 
 
Naadi:    30. Vali                    31. Azhal                 32. Iyam         
   
     33. Valiazhal                 34. Valiiyam                 35. Azhalvali   
 
  
     36. Azhaliyam               37. Iyavali                     38. Iyaazhal    
    
Sparisam:       39. Mithaveppam         40. Miguveppam         
                    
 41. Thatpam 
 
 
INVESTIGATION ( ONLY ON DAY 49) 
 
BLOOD 
 
42. TC (cells /cumm): 
 
43. DC (%):    1. P                   2. L                    3. E                      4. B                  
 
  5. M                       
 
44. Hb (gms %):                  . 
 
45. ESR (mm/hr):        1. 1/2hr                           2.1hr 
 
46. Blood Sugar (R) (mg %): 
 
47. Blood Urea (mg %): 
 
48. Serum Creatinine (mg %):              .  . 
  
49. Serum Cholesterol (mg %): 
 
 
 
 
URINE 
 
50. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +    
                                                                                                                              
51. Sugar:            0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
 
 
52. Deposit                           1. Yes          2. No 
 
1. Pus cells                       
 
2. Epithelial cells             
 
3.. RBC                               
 
4.. Crystals                             
  
 
 
 
53. X – Ray Foot   ----------------------------------------------------------------------------------- 
 
54. RESULT:            Cured                         Improved                       No change 
 
FOR O.P.PATIENTS: 
 
55. Drugs returned: 
    1. No of packs:……………..   
 
 
 
56. Drugs issued 
               1. No of packs-------------- 
 
 
Date:       
Signature of Investigator 
       
Station:                                     
Signature of Doctor 
 
                                   PROTOCOL 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG PALAGARAI  PARPAM  
FOR THE TREATMENT OF VELLAI NOI ( LEUCORRHOEA ) 
                                        - A PILOT STUDY 
         BY 
 
                Dr. P. KAVITHA, PG STUDENT , DEPT. OF GUNAPADAM, NIS, CHENNAI. 
 
 
1. BACKGROUND                  
                Leucorrhoea, vaginal discharge is a universal problem of all women. 
Female genitals are very much prone to infections, since they are moist, more sweaty 
and covered. 
         In Siddha system of medicine, the drugs which are commonly used in the 
treatment of Leucorrhoea includes Parangipattai Choornam and Kungiliya Parpam. 
         In  Pathartha Guna Vilakkam (Thathu Jeeva Varkam) by Kannusami Pillai 
text, there is a preparation of Palagarai Parpam mentioned for Leucorrhoea whose 
efficacy has to be evaluated.  
 
2. ABOUT THE DRUG 
  a. Ingredients 
 Purified Cowrie Shells (Palagarai) 
 Lime Juice 
 
  b. Purification 
 Soak the Palagarai in lime juice and clean it for purification. 
 
  c. Process 
105 grams of Palagarai was put in a mud vessel and soaked with lime juice and 
sun-dried for 2 hours and covered using a mud cap (agal). Then the mud cap and 
the vessel was covered using 7 pieces of clothes (Seelai). Once dried, it was 
calcined by using 30 – 40 cow dung cakes. After heat gets settled, the mud vessel 
was uncovered and a white calx was noticed. The calx was then replaced into a 
different vessel, dried, powdered well and preserved in a vessel. 
 
  d. Indications 
 Vellai, Seetha bethi, Kazhichal and kiragani. 
 
  e. Trial drug,Dosage and Duration  
   Palagarai Parpam – 130 mg b.d. with butter after food for 24 days.  
 
  f. Diet 
 Spicy foods, Brinjal, Bitter guard, Sesban, Tamarind should be avoided. Only 
coolant foods are advised. 
 
 
 
 
 
 g. Mukkutra Vaeruppadu 
 It is mentioned in Theran karisal as  
                   “À¸÷ À¢ò¾ Å¢ó¨¾ÂÄ¡Ð §Á¸õ ÅÃ¡Ð”  
  and  in Sadhaga naadi as,  
 
“ ¯Ú¾¢ÔûÇ À¢ò¾ÁÐ §¾¡ýÈ¢ø ¦ÅôÒ 
¯‰½Å¡ö Åò¾¢ÍÃ Á¾¢ º¡Ãí¸û 
------------------------------------------------------ 
------------------------------------------------------ 
º¢È¢Ð¦ÀÕõÀ¡Î Ãò¾À¢Ã§Á¸í¸û 
 §º÷óÐ Á¢ÌÀ¢½¢ÀÄ×õ º¢ÈìÌó¾¡§É”  
 
     From the above text, naadi for vellai noi is pittham. So it is came to know that 
the siddha aetiology for vellai noi is pittha naadi and due to variation of pittha kutram. 
 
    According to arusuvai theory, 
 
“ À¢ò¾ Á¾¢¸Ã¢ôÀ¢ý §ÀÍõ ÀÃ¢¸¡Ãõ 
Íò¾ò ÐÅ§Ã¡Î ¦º¡øÄ¢É¢ôÒî - ºò¾¡Ìõ 
¨¸ôÒî Í¨Å§Â ¸Õ¾Å¾ý Å£Ú 
±öôÀ¨¼Ô ¦ÁýÚ¨Ãò¾¡ Ã¢íÌ ”  
 
  Kaippu suvai reduces the Pittha kutram, The drug Palagarai has kaippu suvai, so it will 
reduce Pittha kutram. 
 
3. AIMS  
Primary aim 
         To estimate the efficacy of ‘Palagarai Parpam’ in the treatment of Vellai Noi 
(Tricomonas vaginalis).  
. 
Secondary aim 
             To find out the side effects of  the drug, if any. 
           
4. POPULATION AND SAMPLE  
 
 The population consists of Vellai Noi patients (typical vaginal discharge which is 
profuse, thin, creamy or slightly green in colour, Vaginal PH,  vaginal smear for 
Tricomonas vaginalis positive) satisfying the inclusion and exclusion criteria mentioned 
below. 
 
 The sample consists of Vellai Noi patients attending the OPD of Ayothidoss 
Pandidhar Hospital of the National Institute of Siddha, Chennai – 47. 
 
5. SAMPLE SIZE 
           The trial size will be 30 patients aged between 15 – 45 years. 
 
 
 
Font: TSCu_InaiMathi
 
6. SELECTION CRITERIA 
 
    a. Inclusion criteria 
   1. Age 15 – 45 years, 
   2. Willing to attend the OPD once in 6 days for 4 weeks. 
 
    b. Exclusion criteria 
 1. Other Vaginal Infections, 
 2. Blood stained discharge, 
 3. Pregnancy, 
 
   c. Withdrawal criteria 
 1. Severe abdominal pain, 
 2. Any other acute illness. 
 
7. TESTS & ASSESSMENTS  
 
a. Clinical assessment 
1. Vaginal discharge, PH, Tricomonas vaginalis positive. 
2. Pruritus. 
3. Inflammation of Vulva. 
4. Dysuria. 
 
b. Tests 
   Blood 
TC (Cells / Cu mm), DC (%), ESR (mm / hr), Hb (g %), Sugar (mg %), 
VDRL. 
   Urine 
  Albumin, Sugar, Deposit. 
   Vaginal swab - Trichomonas Vaginalis 
              Vaginal PH. 
 
     c.   Siddha assessment 
       
     En vagai thaervu, 
     Neer kuri,  
     Nei kuri. 
 
8. CONDUCT  
 Vellai Noi patients satisfying the inclusion criteria are selected for the study 
(Form1).Informed consent will be obtained from the patients. 
 The trail patients will be issued drugs BID for 6 days at a time. They will be 
instructed to come for next clinical visit after 6 days. Also, they will be asked to bring 
back the unconsumed drug during their next visit and return the same. During each visit, 
patients will be assessed clinically. Lab tests will be carried out before the initiation of 
treatment and at the end of the trial. 
 
 
 
 
9. FORMS  
Form 1 
 Selection proforma used before admission to the trial. 
Form 2 
 Assessment proforma used during clinic visits once in 6 days. 
 
10. ANALYSIS  
                The difference in the proportions of patients with signs& symptoms before and 
after treatment will be analyzed using paired X2 – tests. 
 
 
 
 
 
 
 
AN OPEN CLINICAL TRIAL OF SIDDHA DRUG PALAGARAI PARPAM 
FOR THE TREATMENT OF VELLAI NOI ( LEUCORRHOEA ) 
    
- A PILOT STUDY 
 
   CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 
 I certify that I have disclosed all details about the study in the terms readily understood               
by the patient. 
 
Date: _____________ 
                                                            Signature: ________________ 
Station: ___________ 
                                                            Name: ____________________ 
 
                                              
                                                 CONSENT BY PATIENT 
 
  I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of the drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 
  I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 
  I, exercising my free power of choice, hereby give my consent to be included as a 
subject in the clinical trial of Palagarai parpam on Vellai noi. 
 
  Date: _____________                                            
                                                                Signature: _________________ 
  
 Station: _____________                        Name: _____________________ 
 
                                                                Signature of witness: _____________ 
 
 
 Date: ____________                             Name: ___________________   
   
 Station:  ___________                          Relationship: _________________ 
     
      
 
PROTOCOL 
    
PRE-CLINICAL PHARMACOLOGICAL EVALUATION OF 
PALAGARAI  PARPAM  FOR ANTI- MICROBIAL ACTIVITY    
 
                                             BY 
 
                  Dr. P. KAVITHA, PG STUDENT, DEPT OF GUNAPADAM, NIS, CHENNAI. 
 
1. BACKGROUND 
 
             The drug Palagarai parpam has been mentioned in Pathartha Guna 
Vilakam for vellai, seetha bethi, kazhichal, kiragani. It is believed that this drug will 
have good effect against Leucorrhoea, the common vaginal problem affecting the 
women of reproductive age. So this drug has been selected for the evaluation of 
anti-microbial activity in Leucorrrhoea. 
 
2. AIMS 
 
      Primary aim 
         To assess the anti-microbial activity of Palagarai parpam In vitro. 
       
      Secondary aim 
 1. To evaluate the acute toxicity of Palagarai parpam in swiss albino rats 
through single dose. 
   2. Biochemical analysis. 
   3. Physical properties. 
 
        3. TEST COMPOUND 
                   
                     Palagarai parpam 
 
            Reference:    Pathartha Guna Vilakkam 
 
       4. INTENDED THERAPEUTIC USE 
                       
               Palagarai parpam in the dose of 130 mg b.d with butter is given for                                        
Leucorrhoea 
 
       5. ROUTE OF ADMINISTRATION 
 
                      Oral route 
 
 
 
       
       6. EXPERIMENTAL DETAILS  
 
A. ANTI-MICROBIAL ACTIVITY 
 
DISC DIFFUSION METHOD 
                 The Palagarai parpam is impregnated in standard filter paper 
discs ( 6 mm dm ). The media – sabourauds Dextros Agar or Muller Hinton Agar 20 ml 
per plate ( 90 mm ) are floded with 5 -10 ml of the test inoculam in broth followed by 
flotation method and then drained . the plates are desiccated 15-20 min for adequate 
drying at room temperature. The anti-fungal discs are kept at least 15 mm distance from 
each other    ( 4  - 5 discs can be placed in a 90 mm dm Petri dish ). The plates are 
incubated at 28 degree and the zones of inhibition ( mm dm ) is measured.  
                  
B. ACUTE TOXICITY STUDY 
          Palagarai parpam suspended in Carboxy Methyl Cellulose ( CMC ) will 
be administered to the groups of wister rats in a single oral dose by gavages using a 
feeding needle. The control group receives equal volume of the CMC vehicle. Six female 
rats will be used for each dosage level. Starting dose is 5mg/kg. And the subsequent 
doses are 10, 50, 100, 250, 1000, 2000 and 4000 mg/kg p.o. Observations are made and 
recorded systematically at 1, 2, 4 and 24 hours after substance administration. 
 
OBSERVATIONS 
 
1. Alertness 
2. Aggressiveness 
3. Pile erection 
4. Grooming 
5. Gripping 
6. Touch response 
7. Decreased motor activity 
8. Tremors 
9. Convulsions 
10. Muscle spasm 
11. Catatonia 
12. Muscle relaxant 
13. Hypnosis 
14. Analgesia 
15. Lacrimation 
16. Exopthalmos 
17. Diarrhoea 
18. Writhing 
19. Respiration 
20. Number of deaths (mortality) 
21. Urination. 
22. Oestrous cycle. 
23. Interaction with littering. 
         
AN CLINICAL TRIAL OF SIDDHA DRUG PALAGARAI PARPAM 
FOR THE TREATMENT OF VELLAI NOI ( LEUCORRHOEA ) 
                                                                  - A PILOT STUDY 
FORM-I   SELECTION PROFORMA 
 
 
1. O.P.No / I.P No:  ________ 2.  Bed No: ________ 3. S.No: ________    
 
4. Name: ________________ 5. Age (years):        6. Nationality: _______________ 
 
7. Religion:  ____________8. Occupation: ____________ 9.Income: ______________ 
 
10. Address:  
  
                                                              
11. Complaints and duration:  
 
 
 
12. History of present illness:  
 
  
13. Past history:  
 
 
14. Family history:  
 
 
15. Menstrual & Obstetric history:  
 
 
    
 
Habits                                                                      Yes ( 1 )         No ( 2 ) 
  
 
16. Betalnut chewer                                     
 
17. Tea                  
 
18. Coffee              
 
19. Milk   
                   
20. Non-vegetarian  
 
 
 
 
 
 
GENERAL EXAMINATION   
                                                         
21. Built:          Normosthenic           Hypersthenic           Hyposthenic 
 
22. Nutrition:    Normal         Overweight           Underweight  
 
 
23. Weight (kg)                                                    
      
24. Temperature (°F)        . 
  
25. Pulse rate / minute                                        
 
26. Heart rate / minute        
 
27. Respiratory rate / minute                             
   
28. Blood pressure (mmHg)                              /       / 
 
                                                      1. Yes                   2. No 
29. Pallor                                 
 
30. Jaundice                       
 
31. Cyanosis 
           
32. Lymphadenopathy 
  
33. Pedal oedema  
  
34. Clubbing                                
 
35. Jugular vein pulsation            
    
VITAL ORGANS EXAMINATION 
 
                                    1. Normal            2. Affected 
36. Heart                                                                    _________________ 
 
37. Lungs                                                                   _________________ 
 
38. Brain                                           ________________ 
 
39. Liver              ________________ 
                  
40. Kidney                                                              ________________ 
 
 
41. Spleen                           __________________ 
 
42. Stomach                                     __________________ 
 
CLINICAL EXAMINATION 
 
     SIGNS AND SYMPTOMS            
 
   1. Yes                  2.No 
 
43. White discharge  
          
44. Pruritis vulva                                                                                                                
    
45. Dysuria    
 
46. Lower abdominal pain 
 
47. Low back pain 
 
     PER VAGINA 
 
     VAGINAL DISCHARGE 
   
48. Colour                 1. Yellow               2. Green                 3. White 
 
49. Consistency         1. Thin                   2. Thick                 3. Creamy 
 
50. Amount               1. Mild                   2. Moderate     3     3. Profuse 
 
     1. Yes                        2.No 
   
51. Odour 
 
52. Inflammation of vulva 
 
53. Tenderness 
 
SIDDHA SYSTEM OF EXAMINATON 
 
      IYMPORI 
                                      1. Normal        2. Affected 
  
54. Mei             _____________________ 
 
55. Vaai                    ______________________ 
 
56. Kan              _____________________ 
 
 
 
57. Mookku                        _____________________ 
 
58. Sevi                              _____________________ 
  
KANMENTHIRIUM    
  
59. Kai              _____________________ 
 
60. Kaal        _____________________ 
 
61. Vaai        _____________________ 
 
62. Eruvai        ____________________ 
 
63. Karuvaai        _____________________ 
 
PARUVA  KAALAM 
 
      64. Kaar kaalam         65.Koothir kaalam                
  
     66. Elavenil kaalam          67. Muthuvenil kaalam 
  
   68. Munpani kaalam        69. Pinpani kaalam     
 
THINAI 
 
      70. Kurunji          71. Mullai             72. Marutham     
 
      73. Neithal            74. Paalai 
      
 
YAKKAI 
  75. Vali                76. Azhal           77. Iyam     
  
    78. Valiazhal     79. Valiaiyam           80. Azhalvali   
    
  81. Azhaliyam   82. Iyavali           83. Iyaazhal  
  
 GUNAM 
    84. Sathuva gunam                  85. Rajo gunam              
 
    86. Tamo gunam 
      
 
 
 
 
 
UYIR THATHUKKAL      
 VALI     
                                        1. Normal       2. Affected 
87. Pranan                                        ____________________ 
 
 
88. Abanan                                        _____________________ 
 
89. Samanan                                         ____________________ 
 
90. Udhanan                                        _____________________ 
 
91. Viyanan                                        _____________________ 
 
92. Nagan                                        _____________________ 
 
93. Koorman                                         ____________________ 
 
94. Kirukaran                                       _____________________ 
 
95. Devathathan                                    ______________________ 
 
96. Tananjeyan                  _____________________ 
  
    
 AZHAL 
                                     1. Normal          2. Affected 
 
97. Anala pittham            ____________________ 
 
98. Prasaka pittham             __________________ 
 
99. Ranjaka pittham                       ______________________ 
 
100. Aalosaka pittham               ______________________ 
 
101. Saathaka pittham                ______________________  
      
 IYAM 
                                     1. Normal          2. Affected                                     
 
102. Avalambagam          ______________________ 
 
103. Kilethagam                                                         _____________________  
 
104. Pothagam                         ______________________ 
 
105. Tharpagam                _______________________     
 
107. Santhigam          ______________________ 
 
        
 UDAL THATHUKKAL 
                                     
      1. Normal         2. Affected 
108. Saaram                      _______________________ 
  
109. Chenneer                                                         _______________________ 
 
110. Oon                              _____________________ 
 
111. Kozhuppu                    _______________________ 
 
112. Enbu                       _______________________ 
 
113. Moolai                                      _______________________ 
 
114. Suronitham         _______________________ 
         
 
  ENVAGAI THERVUKAL 
 
                                    1. Normal        2. Affected 
115. Naa                                          _____________________ 
 
116. Niram                                      _____________________ 
 
117. Mozhi                               _____________________ 
 
118. Vizhi                                                            ______________________   
               
    
Malam        1. Normal       2. Affected     
 
119. Niram                  ______________________ 
 
120. Thanmai                  ______________________ 
    
Moothiram          
Neerkuri   
 
121. Niram                         ______________________ 
 
122. Eadai                                       _____________________ 
                                
123. Manam                            ______________________  
 
124. Nurai                         ______________________ 
 
125. Enjal                               ______________________ 
 
 
Neikuri:  126.Vali                        127. Azhal                    128. Iyam      
 
 
Naadi:    129. Vali             130. Azhal                 131. Iyam         
   
     132. Valiazhal                 133. Valiiyam              134. Azhalvali   
  
     135. Azhaliyam               136. Iyavali                 137. Iyaazhal    
    
Sparisam:       138. Mithaveppam         139. Miguveppam         
                    
 140. Thatpam 
 
INVESTIGATION        
BLOOD 
 
141. TC (cells /cumm): 
 
142. DC (%):    1. P                   2. L                    3. E                      4. B                  
 
  5. M                       
 
143. Hb (gms %):                  . 
 
144. ESR (mm/hr):        1. 1/2hr                           2.1hr 
 
145. Blood Sugar (R) (mg %): 
 
146. Blood Urea (mg %): 
 
147. Serum Creatinine (mg %):              .  . 
  
148. Serum Cholesterol (mg %): 
 
149. VDRL                                  1.  Positive             2.  Negative 
 
 
URINE 
 
150. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +                                                                              
151. Sugar:            0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
 
 
 
 
152. Deposit                           1. Yes          2. No 
 
1. Pus cells                       
 
2. Epithelial cells             
 
3.. RBC                               
 
4.. Crystals                             
  
 
  VAGINAL SWAB 
 
 
 
VAGINAL PH______________________________________ 
 
153. ADMITTED TO TRIAL:     1.Yes          2. No   
 
If yes   
 
154. S. No:    
                 
155. I.P / O.P       1. I.P        2. O.P  
 
156. Drug issued for OP patient (g): 
 
 
 
 Station                                            Signature of Investigator 
 
 
 Date                                               Signature of Medical Officer 
                         
                                          
                                                        1    
AN OPEN CLINICAL TRIAL OF PALAGARAI PARPAM   FOR THE 
TREATMENT OF VELLAI NOI ( LEUCORRHOEA ) 
- A PILOT STUDY 
 
FORM II-ASSESSMENT PERFORMA 
 
1. OP/IP No:_________________              2.BED No:_______3.S.No:_______________ 
 
4. NAME:__________________________ 
 
5. DATE OF ADMISSION: 
 
6. DATE OF ASSESSMENT: 
 
7. DAY OF ASSESSMENT: 
 
 
CLINICAL EXAMINATION 
 
     SIGNS AND SYMPTOMS 
            
 
   1. Yes                  2.No 
 
8. White discharge  
          
9. Pruritis vulva                                                                                                                
    
10. Dysuria    
 
11. Lower abdominal pain 
 
12. Low back pain 
 
 
     PER VAGINA 
 
     VAGINAL DISCHARGE 
   
13. Colour                 1. Yellow               2. Green                 3. White 
 
14. Consistency         1. Thin                   2. Thick                 3. Creamy 
 
15. Amount               1. Mild                   2. Moderate     3     3. Profuse 
 
     1. Yes                        2.No 
   
16. Odour 
 
17. Inflammation of vulva 
 
18. Tenderness 
 
  ENVAGAI THERVUKAL 
                                    1. Normal        2. Affected 
19. Naa                                          _____________________ 
 
20. Niram                                      _____________________ 
 
21. Mozhi                               _____________________ 
 
22. Vizhi                                                            ______________________   
          
Malam        1. Normal       2. Affected     
 
23. Niram                  ______________________ 
 
24. Thanmai                  ______________________ 
    
Moothiram    
         
Neerkuri   
 
25. Niram                         ______________________ 
 
26. Eadai                                              _____________________ 
                                
27. Manam                            ______________________  
 
28. Nurai                         ______________________ 
 
29. Enjal                               ______________________ 
 
 
Neikuri:  30.Vali                            31. Azhal                       32. Iyam      
 
 
Naadi:    33. Vali                    34. Azhal                 35. Iyam         
   
     36. Valiazhal                 37. Valiiyam              38. Azhalvali   
  
     39. Azhaliyam               40. Iyavali                 41. Iyaazhal    
    
Sparisam:       42. Mithaveppam         43. Miguveppam         
                    
 44. Thatpam 
 
INVESTIGATION ( ONLY ON DAY 25) 
 
BLOOD 
 
45. TC (cells /cumm): 
 
46. DC (%):    1. P                   2. L                    3. E                      4. B                  
 
  5. M                       
 
47. Hb (gms %):                  . 
 
48. ESR (mm/hr):        1. 1/2hr                           2.1hr 
 
49. Blood Sugar (R) (mg %): 
 
50. Blood Urea (mg %): 
 
51. Serum Creatinine (mg %):              .  . 
  
52. Serum Cholesterol (mg %): 
 
53. VDRL                                  1.  Positive             2.  Negative 
 
 
 
 
URINE 
 
54. Albumin:      0. Nil  1. Trace  2. +  3. + + 
  
    4. + + +    
                                                                                                                             
55. Sugar:            0. Nil  1. Trace  2. +   3. + +         
 
      4. + + + 
 
 
56. Deposit                           1. Yes          2. No 
 
1. Pus cells                       
 
2. Epithelial cells             
 
3. RBC                               
 
4. Crystals                             
  
 MOTION                         
                                      1. Yes         2.No    
57. Ova                           
 
58. Cyst                           
 
59. Occult blood              
 
 
VAGINAL SWAB 
 
 
 
 
60. RESULT:            Cured                         Improved                       No change 
 
FOR O.P.PATIENTS: 
 
61. Drugs returned 
    1. No of packs------------  
 
 
62. Drugs issued 
             1. No of packs-------------- 
 
 
Date:       
Signature of Investigator 
       
Station:                                     
Signature of Doctor 
 
 
 
